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A B S T R A C T
Background
Self-monitoring of blood glucose (SMBG) is recommended as a key component of the management plan for diabetes therapy during
pregnancy. No existing systematic reviews consider the benefits/eHectiveness of various techniques of blood glucose monitoring on
maternal and infant outcomes among pregnant women with pre-existing diabetes. The eHectiveness of the various monitoring techniques
is unclear.
Objectives
To compare techniques of blood glucose monitoring and their impact on maternal and infant outcomes among pregnant women with pre-
existing diabetes.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (30 November 2016), searched reference lists of retrieved
studies and contacted trial authors.
Selection criteria
Randomised controlled trials (RCTs) and quasi-RCTs comparing techniques of blood glucose monitoring including SMBG, continuous
glucose monitoring (CGM) or clinic monitoring among pregnant women with pre-existing diabetes mellitus (type 1 or type 2). Trials
investigating timing and frequency of monitoring were also included. RCTs using a cluster-randomised design were eligible for inclusion
but none were identified.
Data collection and analysis
Two review authors independently assessed study eligibility, extracted data and assessed the risk of bias of included studies. Data were
checked for accuracy. The quality of the evidence was assessed using the GRADE approach.
Main results
This review update includes at total of 10 trials (538) women (468 women with type 1 diabetes and 70 women with type 2 diabetes). The
trials took place in Europe and the USA. Five of the 10 included studies were at moderate risk of bias, four studies were at low to moderate
risk of bias, and one study was at high risk of bias. The trials are too small to show diHerences in important outcomes such as macrosomia,
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preterm birth, miscarriage or death of baby. Almost all the reported GRADE outcomes were assessed as being very low-quality evidence.
This was due to design limitations in the studies, wide confidence intervals, small sample sizes, and few events. In addition, there was high
heterogeneity for some outcomes.
Various methods of glucose monitoring were compared in the trials. Neither pooled analyses nor individual trial analyses showed any clear
advantages of one monitoring technique over another for primary and secondary outcomes. Many important outcomes were not reported.
1. Self-monitoring versus standard care (two studies, 43 women): there was no clear diHerence for caesarean section (risk ratio (RR) 0.78,
95% confidence interval (CI) 0.40 to 1.49; one study, 28 women) or glycaemic control (both very low-quality), and not enough evidence
to assess perinatal mortality and neonatal mortality and morbidity composite. Hypertensive disorders of pregnancy, large-for-gestational
age, neurosensory disability, and preterm birth were not reported in either study.
2. Self-monitoring versus hospitalisation (one study, 100 women): there was no clear diHerence for hypertensive disorders of pregnancy
(pre-eclampsia and hypertension) (RR 4.26, 95% CI 0.52 to 35.16; very low-quality: RR 0.43, 95% CI 0.08 to 2.22; very low-quality). There was
no clear diHerence in caesarean section or preterm birth less than 37 weeks' gestation (both very low quality), and the sample size was too
small to assess perinatal mortality (very low-quality). Large-for-gestational age, mortality or morbidity composite, neurosensory disability
and preterm birth less than 34 weeks were not reported.
3. Pre-prandial versus post-prandial glucose monitoring (one study, 61 women): there was no clear diHerence between groups for
caesarean section (RR 1.45, 95% CI 0.92 to 2.28; very low-quality), large-for-gestational age (RR 1.16, 95% CI 0.73 to 1.85; very low-quality)
or glycaemic control (very low-quality). The results for hypertensive disorders of pregnancy: pre-eclampsia and perinatal mortality are not
meaningful because these outcomes were too rare to show diHerences in a small sample (all very low-quality). The study did not report the
outcomes mortality or morbidity composite, neurosensory disability or preterm birth.
4. Automated telemedicine monitoring versus conventional system (three studies, 84 women): there was no clear diHerence for
caesarean section (RR 0.96, 95% CI 0.62 to 1.48; one study, 32 women; very low-quality), and mortality or morbidity composite in the
one study that reported these outcomes. There were no clear diHerences for glycaemic control (very low-quality). No studies reported
hypertensive disorders of pregnancy, large-for-gestational age, perinatal mortality (stillbirth and neonatal mortality), neurosensory
disability or preterm birth.
5.CGM versus intermittent monitoring (two studies, 225 women): there was no clear diHerence for pre-eclampsia (RR 1.37, 95% CI 0.52 to
3.59; low-quality), caesarean section (average RR 1.00, 95% CI 0.65 to 1.54; I2 = 62%; very low-quality) and large-for-gestational age (average
RR 0.89, 95% CI 0.41 to 1.92; I2 = 82%; very low-quality). Glycaemic control indicated by mean maternal HbA1c was lower for women in the
continuous monitoring group (mean diHerence (MD) -0.60 %, 95% CI -0.91 to -0.29; one study, 71 women; moderate-quality). There was
not enough evidence to assess perinatal mortality and there were no clear diHerences for preterm birth less than 37 weeks' gestation (low-
quality). Mortality or morbidity composite, neurosensory disability and preterm birth less than 34 weeks were not reported.
6. Constant CGM versus intermittent CGM (one study, 25 women): there was no clear diHerence between groups for caesarean section
(RR 0.77, 95% CI 0.33 to 1.79; very low-quality), glycaemic control (mean blood glucose in the 3rd trimester) (MD -0.14 mmol/L, 95% CI
-2.00 to 1.72; very low-quality) or preterm birth less than 37 weeks' gestation (RR 1.08, 95% CI 0.08 to 15.46; very low-quality). Other
primary (hypertensive disorders of pregnancy, large-for-gestational age, perinatal mortality (stillbirth and neonatal mortality), mortality
or morbidity composite, and neurosensory disability) or GRADE outcomes (preterm birth less than 34 weeks' gestation) were not reported.
Authors' conclusions
This review found no evidence that any glucose monitoring technique is superior to any other technique among pregnant women with
pre-existing type 1 or type 2 diabetes. The evidence base for the eHectiveness of monitoring techniques is weak and additional evidence
from large well-designed randomised trials is required to inform choices of glucose monitoring techniques.
P L A I N   L A N G U A G E   S U M M A R Y
Methods for monitoring blood glucose in pregnant women with diabetes to improve outcomes
What is the issue?
If a mother already has diabetes when she becomes pregnant, she and her baby are at a higher risk of various problems in pregnancy,
labour, birth and later. During pregnancy, the mother will have her blood glucose levels (sometimes referred to as blood sugar levels)
monitored so appropriate steps can be taken to control her blood glucose. This Cochrane review looked for the best test for measuring
blood glucose during pregnancy in order to control blood glucose levels and so reduce problems for babies and mothers. We collected and
analysed all relevant studies to answer this question (search date: November 2016).
Why is this important?
Diabetes can cause problems for pregnant women and their babies, including early births, large babies, diHicult births and the need for
caesarean section. The problems also include a risk to the baby of bleeding in the brain (intracranial haemorrhage), and during labour,
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there is an increased risk of the baby’s shoulder becoming stuck (shoulder dystocia). ASer the birth, there is an increased risk of low blood
sugar (hypoglycaemia), jaundice and breathing problems. The babies are more likely to be admitted to an intensive care unit. Later, there
is an increased risk of the baby developing diabetes as a child.
Women with existing diabetes that is not well-controlled at the time of conception and in the first three months of pregnancy are at
increased risk of miscarriage, of having a baby with developmental problems or stillbirth. Several methods for monitoring blood glucose
levels are used including regular testing at antenatal clinics, self-monitoring, or the use of special equipment that can continuously monitor
glucose levels during pregnancy. A more accurate measure of blood sugar may lead to more eHective control of blood glucose and a
reduction in the potential problems for babies and mothers.
What evidence did we find?
We found 10 trials involving 538 women and babies. We found studies that compared various methods of glucose monitoring: self-
monitoring versus standard care, self-monitoring versus hospitalisation, monitoring before meals versus monitoring aSer meals, glucose
monitoring, automated monitoring versus conventional system, continuous glucose monitoring (CGM) versus intermittent monitoring
and constant CGM versus intermittent CGM. The trials were from European countries and the USA. They looked at diHerent techniques of
monitoring and reported on diHerent outcomes. The number of women in each study was generally small. The evidence was mostly of
very low-quality, so we cannot be certain of the results.
The results did not show that any one monitoring technique was better than others. There was no clear diHerence between the monitoring
techniques when mothers’ control of blood glucose or high blood pressure disorders were looked at. Similarly, we found no diHerence in
rates of caesarean section, the number of large babies, the number of babies who died or had serious health problems, or the number
of babies being born too early (preterm). We do not know if this is because there is no diHerence between the techniques, or if there is a
diHerence that these studies did not manage to show.
What does this mean?
The review showed that there is not enough evidence to say with any certainty which monitoring method for blood glucose is best. More
research is needed to find out which monitoring method, if any, is best at reducing the risk of complications.
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Summary of findings for the main comparison.   Self-monitoring compared to standard care for women with pre-existing diabetes
Self-monitoring compared to standard care for women with pre-existing diabetes
Patient or population: women with pre-existing diabetes
Setting: one study in the USA
Intervention: self-monitoring
Comparison: standard care
Anticipated absolute effects* (95% CI)Outcomes
Risk with standard
care
Risk with self-monitoring
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationHypertensive disor-
ders of pregnancy: pre-
eclampsia    
  (0 studies)   The included study did not report
this outcome.
Study populationHypertensive disorders
of pregnancy: gesta-
tional hypertension    
  (0 studies)   The included study did not report
this outcome.
Study populationCaesarean section
643 per 1000 501 per 1000
(257 to 958)
RR 0.78
(0.40 to 1.49)
28
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Glycaemic control dur-
ing/end of treatment:
Maternal HbA1c (%)
The mean maternal
HbA1c was 7.2%
The mean maternal HbA1c
with self-monitoring was
0.10 lower (1.93 lower to
1.73 higher)
  28
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 3
 
Glycaemic control dur-
ing/end of treatment:
Maternal post-prandi-
al blood glucose (mm-
mol/L)
The mean mater-
nal post-prandial
blood glucose was
5.3 mmol/L
MD 0.70 lower
(2.15 lower to 0.75 higher)
  13
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 3
 
Study populationLarge-for-gestational
age
   
  (0 studies)   The included study did not report
this outcome.
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Study populationPerinatal mortality
0 per 1000 0 per 1000
(0 to 0)
RR 3.00
(0.13 to 67.91)
28
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
There were no events in the standard
care group and so anticipated ab-
solute effects could not be calculat-
ed.
Study populationPreterm birth less than
37 weeks' gestation
   
  (0 studies)   The included study did not report
this outcome.
Study populationPreterm birth less than
34 weeks' gestation
   
  (0 studies)   The included study did not report
this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 One study with design limitations.
2 Wide CI crossing the line of no eHect, few events and small sample size.
3 Wide CI crossing the line of no eHect, and small sample size.
 
 
Summary of findings 2.   Self-monitoring compared to hospitalisation for women with pre-existing diabetes
Self-monitoring compared to hospitalisation for women with pre-existing diabetes
Patient or population: women with pre-existing diabetes
Setting: one study in Sweden
Intervention: Self-monitoring
Comparison: hospitalisation
Anticipated absolute effects* (95% CI)Outcomes
Risk with hospi-
talisation
Risk with self-monitor-
ing
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
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Study populationHypertensive disorders of pregnancy: pre-
eclampsia
22 per 1000 93 per 1000
(11 to 764)
RR 4.26
(0.52 to 35.16)
100
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationHypertensive disorders of pregnancy: hy-
pertension in pregnancy
87 per 1000 37 per 1000
(7 to 193)
RR 0.43
(0.08 to 2.22)
100
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationCaesarean section
500 per 1000 480 per 1000
(325 to 720)
RR 0.96
(0.65 to 1.44)
100
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Glycaemic control during/end of treatment:
maternal HbA1c
      (0 studies)   The included study
did not report this out-
come.
Glycaemic control during/end of treatment:
maternal post-prandial blood glucose
      (0 studies)   The included study
did not report this out-
come.
Study populationLarge-for-gestational age
   
  (0 studies)   The included study
did not report this out-
come.
Study populationPerinatal mortality
22 per 1000 18 per 1000
(1 to 288)
RR 0.85
(0.05 to 13.24)
100
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationPreterm birth less than 37 weeks' gestation
304 per 1000 259 per 1000
(137 to 487)
RR 0.85
(0.45 to 1.60)
100
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationPreterm birth less than 34 weeks' gestation
   
  (0 studies)   The included study
did not report this out-
come.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
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CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 One study with design limitations.
2 Wide CI crossing the line of no eHect, few events and small sample size.
 
 
Summary of findings 3.   Pre-prandial compared to post-prandial glucose monitoring for women with pre-existing diabetes
Pre-prandial compared to post-prandial glucose monitoring for women with pre-existing diabetes
Patient or population: women with pre-existing diabetes
Setting: one study in the UK
Intervention: pre-prandial
Comparison: post-prandial glucose monitoring
Anticipated absolute effects* (95% CI)Outcomes
Risk with post-
prandial glucose
monitoring
Risk with pre-prandial
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationHypertensive disorders of preg-
nancy: pre-eclampsia
33 per 1000 214 per 1000
(27 to 1000)
RR 6.43
(0.82 to 50.11)
58
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationHypertensive disorders of preg-
nancy: gestational hyperten-
sion    
  (0 studies)   The included study did not
report this outcome.
Study populationCaesarean section
467 per 1000 677 per 1000
(429 to 1000)
RR 1.45
(0.92 to 2.28)
61
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Glycaemic control during/end
of treatment: HbA1c (%)
The mean hbA1c
was 6%
The mean maternal HbA1c with
pre-prandial monitoring as 0.30
  61
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 3
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higher (0.08 lower to 0.68 high-
er)
Glycaemic control during/end
of treatment: post-prandial
blood glucose
      (0 studies)   The included study did not
report this outcome.
Study populationLarge-for-gestational age
500 per 1000 580 per 1000
(365 to 925)
RR 1.16
(0.73 to 1.85)
61
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationPerinatal mortality
0 per 1000 0 per 1000
(0 to 0)
RR 2.91
(0.12 to 68.66)
61
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
There were no events in
the standard care group
and so anticipated ab-
solute effects could not be
calculated.
Study populationPreterm birth less than 37
weeks
267 per 1000 355 per 1000
(165 to 757)
RR 1.33
(0.62 to 2.84)
61
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationPreterm birth less than 34
weeks' gestation
   
  (0 studies)   The included study did not
report this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 One study with design limitations.
2 Wide CI crossing the line of no eHect, few events and small sample size.
3 Wide CI crossing the line of no eHect, and small sample size.
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Summary of findings 4.   Automated telemedicine monitoring compared to conventional for women with pre-existing diabetes
Automated telemedicine monitoring compared to conventional for women with pre-existing diabetes
Patient or population: women with pre-existing diabetes
Setting: two studies in Italy, one study in Poland
Intervention: automated telemedicine monitoring
Comparison: conventional monitoring
Anticipated absolute effects* (95% CI)Outcomes
Risk with convention-
al monitoring
Risk with automated telemedicine
monitoring
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationHypertensive disor-
ders of pregnancy:
pre-eclampsia, ges-
tational hyperten-
sion
   
  (0 studies)   The included studies did not
report this outcome.
Study populationHypertensive disor-
ders of pregnancy:
gestational hyper-
tension
   
  (0 studies)   The included studies did not
report this outcome.
Study populationCaesarean section
733 per 1000 704 per 1000
(455 to 1000)
RR 0.96
(0.62 to 1.48)
32
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Glycaemic con-
trol during/end of
treatment: mater-
nal HbA1c (%)
The mean maternal
HbA1c ranged from 5.7
to 6.7%
The mean maternal HbA1c with au-
tomated telemedicine monitoring as
0.17 lower (0.82 lower to 0.48 higher)
  82
(3 RCTs)
⊕⊝⊝⊝
VERY LOW 3 4 5
 
Glycaemic con-
trol during/end of
treatment: mater-
nal post-prandi-
al blood glucose
(mmol/L)
The mean maternal
post-prandial blood
glucose ranged from
6.9 to 7.6%
The mean post-prandial blood glu-
cose with automated telemedicine
monitoring as 0.80 lower (1.67 lower
to 0.08 higher)
  50
(2 RCTs)
⊕⊝⊝⊝
VERY LOW 3 5 6
 
Large-for-gesta-
tional age
Study population   (0 studies)   The included studies did not
report this outcome.
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Study populationPerinatal mortality
   
  (0 studies)   The included studies did not
report this outcome.
Study populationPreterm birth less
than 37 weeks' ges-
tation    
  (0 studies)   The included studies did not
report this outcome.
Study populationPreterm birth less
than 34 weeks' ges-
tation    
  (0 studies)   The included studies did not
report this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 One study with serious design limitations.
2 Wide CI crossing the line of no eHect, few events and small sample size.
3 Studies had design limitations.
4 Statistical heterogeneity (I2 = 82%).
5 Wide CI crossing the line of no eHect, and small sample size.
6 Statistical heterogeneity (I2 = 86%).
 
 
Summary of findings 5.   Continuous glucose monitoring compared to intermittent glucose monitoring for women with pre-existing diabetes
Continuous glucose monitoring compared to intermittent glucose monitoring for women with pre-existing diabetes
Patient or population: women with pre-existing diabetes
Setting: one study in Denmark, one study in the UK
Intervention: continuous glucose monitoring
Comparison: intermittent glucose monitoring
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Anticipated absolute effects* (95% CI)Outcomes
Risk with intermit-
tent glucose moni-
toring
Risk with continuous glucose mon-
itoring
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationHypertensive disorders of pregnan-
cy: pre-eclampsia
56 per 1000 76 per 1000
(29 to 199)
RR 1.37
(0.52 to 3.59)
225
(2 RCTs)
⊕⊕⊝⊝
LOW 1
 
Study populationHypertensive disorders of pregnan-
cy: gestational hypertension
   
  (0 studies)   The included
studies did not
report this out-
come.
Study populationCaesarean section
481 per 1000 481 per 1000
(313 to 741)
RR 1.00
(0.65 to 1.54)
225
(2 RCTs)
⊕⊝⊝⊝
VERY LOW 2 3
 
Glycaemic control during/end of
treatment: maternal HbA1c (%)
The mean maternal
HbA1c was 6.4%
The mean maternal HbA1c with con-
tinuous glucose monitoring was 0.60
lower (0.91 lower to 0.29 higher)
  71
(1 RCT)
⊕⊕⊕⊝
MODERATE 4
 
Glycaemic control during/end of
treatment: post-prandial blood
glucose
      (0 studies)   The included
studies did not
report this out-
come.
Study populationLarge-for-gestational age
410 per 1000 364 per 1000
(168 to 786)
RR 0.89
(0.41 to 1.92)
221
(2 RCTs)
⊕⊝⊝⊝
VERY LOW 3 5
 
Study populationPerinatal mortality
31 per 1000 26 per 1000
(2 to 394)
RR 0.82
(0.05 to 12.61)
71
(1 RCT)
⊕⊕⊝⊝
LOW 1
 
Study populationPreterm birth less than 37 weeks
167 per 1000 183 per 1000
(105 to 323)
RR 1.10
(0.63 to 1.94)
228
(2 RCTs)
⊕⊕⊝⊝
LOW 1
 
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Techniques of m
onitoring blood glucose during pregnancy for w
om
en w
ith pre-existing diabetes (Review
)
Copyright ©
 2017 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
12
Study populationPreterm birth less than 34 weeks'
gestation
   
  (0 studies)   The included
studies did not
report this out-
come.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Wide CI crossing the line of no eHect, few events and small sample size.
2 Statistical heterogeneity (I2 = 62%).
3 Wide CI crossing the line of no eHect, and small sample size.
4 Small sample size.
5 Statistical heterogeneity (I2 = 82%).
 
 
Summary of findings 6.   Constant CGM compared to Intermittent CGM for women with pre-existing diabetes
Constant CGM compared to Intermittent CGM for women with pre-existing diabetes
Patient or population: women with pre-existing diabetes
Setting: one study in Macedonia
Intervention: constant CGM
Comparison: intermittent CGM
Anticipated absolute effects* (95% CI)Outcomes
Risk with Intermit-
tent CGM
Risk with constant CGM
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Study populationHypertensive disorders of
pregnancy: pre-eclampsia
   
  (0 studies)   The included study did
not report this outcome.
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Study populationHypertensive disorders of
pregnancy: gestational hy-
pertension    
  (0 studies)   The included study did
not report this outcome.
Study populationCaesarean section
538 per 1000 415 per 1000
(178 to 964)
RR 0.77
(0.33 to 1.79)
25
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Glycaemic control dur-
ing/end of treatment:
maternal HbA1c (3rd
trimester) (%)
The mean maternal
HbA1c (3rd trimester)
was 6.23%
The mean maternal HbA1c with
constant CGM was 0.09 lower (0.69
lower to 0.51 higher)
  25
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 3
 
Glycaemic control dur-
ing/end of treatment: ma-
ternal blood glucose (3rd
trimester) (mmmol/L)
The mean maternal
blood glucose (3rd
trimester) was 0
The mean maternal blood glucose
(3rd trimester) with constant CGM
was 0.14 lower (2.00 lower to 1.72
higher)
  25
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 3
 
Study populationLarge-for-gestational age
   
  (0 studies)   The included study did
not report this outcome.
Study populationPerinatal mortality
   
  (0 studies)   The included study did
not report this outcome.
Study populationPreterm birth less than 37
weeks' gestation
77 per 1000 83 per 1000
(6 to 1000)
RR 1.08
(0.08 to 15.46)
25
(1 RCT)
⊕⊝⊝⊝
VERY LOW 1 2
 
Study populationPreterm birth less than 34
weeks' gestation
   
  (0 studies)   The included study did
not report this outcome.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High quality: We are very confident that the true effect lies close to that of the estimate of the effect
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Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is sub-
stantially different
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 One study with design limitations.
2 Wide CI crossing the line of no eHect, few events and small sample size.
3 Wide CI crossing the line of no eHect, and small sample size.
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B A C K G R O U N D
Description of the condition
Types of diabetes
There are three main types of diabetes mellitus: type 1, type
2 and gestational diabetes mellitus (GDM). Type 1 or insulin-
dependent diabetes results from the body’s failure to produce
suHicient insulin and accounts for a minority of the total burden
of diabetes in a population. Type 2 diabetes results from a failure
of the body to utilise insulin, causing high blood sugar levels. Type
2 diabetes alone constitutes about 85% to 95% of all diabetes
globally (IDF 2010). Type 2 diabetes is a serious and growing global
health problem that has evolved in association with rapid cultural
and social changes, ageing populations, increasing urbanisation,
dietary changes, reduced physical activity and other unhealthy
lifestyle and behavioural patterns (WHO 1994). In GDM, women who
were not previously diabetic develop carbohydrate intolerance
resulting in hyperglycaemia (high blood sugar levels) with first
onset or detection occurring during pregnancy (HAPO 2002). GDM
develops in one in 25 pregnancies worldwide and it is associated
with the increasing incidence of type 2 diabetes post-pregnancy.
Prevalence of diabetes
Diabetes mellitus is found in every population in the world and it
is estimated that 6.6% of the global population in the age group of
20 to 79 years old had diabetes in 2010. By 2030, it is estimated that
7.8% of the adult population will have diabetes (IDF 2010).
Diabetes mellitus complicates about 2% to 3% of all pregnancies.
Approximately 90% of diabetes in pregnancy is accounted for by
GDM. Pre-existing type 1 and type 2 diabetes account for the
remaining 10% of diabetes during pregnancy (Moore 2010). This
review considers only the management of pre-existing diabetes in
pregnant women as a separate Cochrane review on GDM is being
prepared (Gill 2014).
Complications of diabetes in pregnancy: for mother and baby
Women with diabetes of any kind are at increased risk of morbidity
and mortality during pregnancy.  Pregnancy outcomes for women
with pre-existing diabetes and their infants are poor compared to
those for women who do not have diabetes (NICE 2008). The risks
to both women and infants include fetal macrosomia (large baby),
preterm birth, birth trauma (to mother and infant), induction of
labour or caesarean section, miscarriage, congenital malformation,
stillbirth, transient neonatal morbidity, neonatal death, obesity
and/or diabetes developing later in the baby’s life (Gonzalez-
Gonzalez 2008; Kitzmiller 2008; NICE 2008).
Women with diabetes have an increased risk of an early miscarriage
and are at increased risk of having a baby with malformations.
Both of these risks are associated with less than optimal
glycaemic control around the time of conception and in the first
trimester. The risks appear to be approximately equivalent for
women with type 1 and type 2 diabetes. The increased rate of
spontaneous miscarriages and fetal malformation appear to be
low when glycaemic control is moderately raised, and higher
with increasingly poor glycaemic control (IDF 2010; Jensen 2009).
Women with diabetes should be encouraged to obtain the best
possible glycaemic control before conception (Kitzmiller 2010).
Women with uncontrolled glycaemic levels should be discouraged
from becoming pregnant until their blood glucose control can be
improved.
Macrosomia, defined as infant birthweight greater than 4.5 kg,
remains the commonest complication of pregnancy in women
with diabetes (IDF 2010; Kitzmiller 2008; NICE 2008). Macrosomia
occurs in 27% to 62% of infants of diabetic mothers compared
with 10% of non-diabetic mothers (Gabbe 2003). Nationwide
studies from the Netherlands, the UK, and Denmark estimate that
the risk of delivering a large-for-gestational age, or macrosomic
infant in women with type 1 diabetes ranges from 48.8% to
62.5% (Kitzmiller 2008). Recent data confirm that women with
type 2 diabetes have an equally high risk of delivering a
macrosomic infant (ACOG 2005; ADA 2004; Roland 2005). For
mothers with diabetes, macrosomia leads to an increased risk
of perineal lacerations, complications in labour, and delivery by
caesarean section (Slocum 2004). There are increased risks for the
infants of intracranial haemorrhage, shoulder dystocia, neonatal
hypoglycaemia, jaundice, and respiratory distress (Thomas 2006),
as well as the longer-term health risks of insulin resistance,
obesity and type 2 diabetes (McElduH 2005). Overt diabetes is an
undisputed factor for preterm birth (Sibai 2000).
Fetal hyperglycaemia causes fetal hypoxia and acidosis, which may
explain the excess stillbirth rates observed in women with poorly
controlled diabetes (Kitzmiller 2008). Infants with macrosomia due
to poor maternal glycaemic control and fetal hyperinsulinaemia are
more likely to develop obesity and glucose intolerance later in life
(Fetita 2006; Kitzmiller 2008). Long-term (five to 15 years) follow-
up studies of infants of mothers with diabetes suggest that poor
glycaemic control during pregnancy has a negative influence on
intellectual and psychomotor development (Kitzmiller 2008). Both
findings highlight the prolonged eHects on oHspring of intrauterine
exposure to diabetes (Fetita 2006; Kitzmiller 2008).
Glycaemic control prior to conception and in early pregnancy
The increased risks in women with diabetes of an early miscarriage
and of having a baby with malformations are associated with
suboptimal glycaemic control before or around the time of
conception, and in the first trimester. Guidelines recommend that
women should achieve the best possible glycaemic control before
conception: women who improve their glycaemic control before
conception have a reduced rate of fetal malformation (Fuhrmann
1983; IDF 2010; NICE 2008).
Maternal hyperglycaemia during the first few weeks of pregnancy
is strongly associated with increased spontaneous abortions
and major congenital malformations (Kitzmiller 1996; Ray
2001). ASer 12 weeks’ gestation, hyperglycaemia induces fetal
hyperinsulinaemia, accelerated growth, and excess adiposity in
animal models and in women with diabetes (Gabbe 2003). These
risks appear to be approximately equivalent for women with
type 1 and type 2 diabetes. The increased rate of spontaneous
miscarriages appears to be low when the HbA1c is modestly raised,
and higher with increasingly poor glycaemic control (Mills 1988;
Rosenn 1991). The same pattern is also found with respect to the
rate of fetal malformations (Greene 1989; Suhonen 2000).
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Description of the intervention
Techniques of blood glucose monitoring
Glucose readings supply trend information that helps to identify
and prevent unwanted periods of hypo- and hyperglycaemia that
are associated with adverse outcomes for both mother and baby.
Women with type 1 and type 2 diabetes are advised to self-monitor
their blood glucose throughout pregnancy (IDF 2010).
Techniques of blood glucose monitoring to be considered in
this review include self-monitoring of blood glucose (SMBG),
continuous glucose monitoring (CGM) and clinic monitoring (for
which timing and frequency of monitoring are also considered).
1. Self-monitoring of blood glucose (SMBG) - a glucose meter
(glucometer), with or without memory, can be used to measure
capillary glucose. Conventional intensified glucose monitoring
is defined as three to four blood glucose measurements per day
(ADA 2011). Post-prandial glucose during pregnancy has been
identified as the best   predictor of neonatal   macrosomia  (de
Veciana 1995; Moses 1999). Therefore, SMBG protocols for
women with type 1 or type 2 diabetes during pregnancy
stress the importance of measuring blood glucose aSer meals
(Jovanovič 2009) while for non-pregnant women with diabetes,
pre-prandial values are recommended (ADA 2011; NICE 2008).
2. Continuous glucose monitoring (CGM) - the continuous glucose
monitors currently available measure blood glucose either
with minimal invasiveness  through  continuous measurement
of interstitial fluid (ISF) or with the non-invasive method of
applying electromagnetic radiation through the skin to blood
vessels in the body. The technologies for bringing a sensor
into contact with ISF include inserting an indwelling sensor
subcutaneously (into the abdominal wall or arm) to measure
ISF in situ or harvesting this fluid by various mechanisms that
compromise the skin barrier and delivering the fluid to an
external sensor (Choleau 2002). ASer a warm-up period of up
to two hours and a device-specific calibration process, each
device’s sensor provides a blood glucose reading every one
to 10 minutes for up to 72 hours with the minimally invasive
technology and up to three months with the non-invasive
technology. CGM can provide up to 288 measurements a day
(Murphy 2007).
3. Clinic monitoring refers to routine glucose monitoring during
antenatal visits either using capillary or whole blood.
Timing and frequency of glucose monitoring
Post-prandial glucose monitoring has been shown to be able to
improve glycaemic control and thus reduce the risk of neonatal
hypoglycaemia, macrosomia and caesarean delivery (de Veciana
1995), as well as to reduce the incidence of pre-eclampsia
and neonatal triceps skinfold thickness (Manderson 2003). Post-
prandial glucose values were most strongly associated with
increased birthweight in the studies in which both pre- and post-
meal glucose were measured (Mello 2000).
Pregnant women with diabetes mellitus are advised to test fasting
and one-hour post-prandial blood glucose levels aSer every meal
during pregnancy and those taking insulin are encouraged to test
their blood glucose before going to bed at night (NICE 2008). The
American Diabetes Association also recommends SMBG before and
aSer meals and occasionally at night time, to provide optimal
results in pregnancy (Kitzmiller 2008).
The optimal frequency and timing of home glucose testing
during pregnancy is unknown. In reality the frequency of glucose
monitoring will depend on women's compliance, with few
managing to carry out high numbers of tests daily (Kerssen 2006).
Educational approaches incorporating additional glucose testing
aSer meals to improve glycaemic control in late gestation have
shown potential to reduce birthweight (Howorka 2001).
Glycaemic control during pregnancy among women with pre-
existing diabetes
Pregnancy profoundly aHects the management of diabetes (Gabbe
2003; Jovanovic 2006). Pregnancy is associated with changes in
insulin sensitivity, which may lead to changes in plasma glucose
levels. Hormonal changes during pregnancy cause a progressive
increase in insulin resistance, necessitating intensive medical
nutrition therapy and frequently adjusted insulin administration
throughout the pregnancy. The control of hyperglycaemia in
pregnant women with pre-existing diabetes is essential in order to
avoid the above mentioned adverse maternal and infant outcomes
(Kitzmiller 2008). Macrosomia and other neonatal complications
are minimised with intensified glycaemic control (Kerssen 2007;
Kitzmiller 2008; Suhonen 2000).
If it is safely achievable, women with diabetes should aim to
keep fasting blood glucose between 3.5 mmol/L and 5.9 mmol/
L and one-hour post-prandial blood glucose below 7.8 mmol/L
during pregnancy (NICE 2008); HbA1c should be kept below 6.0%
(ADA 2011). Excellent glycaemic control throughout the pregnancy
is associated with the lowest risk for both maternal, fetal and
neonatal complications (Kitzmiller 2008). On the other hand, the
targets of glycaemic control for non-pregnant women with type 1
or type 2 diabetes are less stringent, i.e. fasting blood glucose to be
3.9 mmol/L to 7.2 mmol/L and HbA1c less than 7.0% (ADA 2011).
How the intervention might work
Maternal glucose levels in women with pre-existing diabetes
directly influence those of the fetus. Fetal metabolic complications
may give rise to macrosomia, congenital malformation, stillbirth
and increased perinatal mortality (IDF 2010; Kapoor 2007;
Kitzmiller 2008; NICE 2008). Blood glucose monitoring allows
adjustment of insulin dosage in relation to meal size and type,
physical activity, stress and time of the day for women with
pre-existing diabetes during pregnancy (Davidson 2005). This will
limit the maternal risk of hypoglycaemic episodes while avoiding
prolonged periods of hyperglycaemia. However, the frequency and
timing of glucose monitoring will also influence the maternal and
fetal outcome.
Why it is important to do this review
Self-monitoring of blood glucose is recommended as a key
component of diabetes therapy during pregnancy and included
in the management plan (IDF 2010; Kitzmiller 2008; NICE 2008).
No existing systematic reviews consider the benefits of various
techniques of blood glucose monitoring on maternal and infant
outcomes among pregnant women with pre-existing diabetes. The
eHectiveness of the various monitoring techniques is unclear. This
systematic review aims to generate information to guide pregnant
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women with pre-existing diabetes and their clinicians in their
choice of monitoring techniques in order to optimise maternal and
infant outcomes. All trials that evaluate any techniques of blood
glucose monitoring among pregnant women with pre-existing
diabetes will be considered.
O B J E C T I V E S
To compare the techniques of blood glucose monitoring and their
impact on maternal and infant outcomes among pregnant women
with pre-existing diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials, and in this version of
the review, one quasi-experimental trial. Cluster-randomised trials
were eligible for inclusion but none were identified. Trials using
a cross-over design were not eligible for inclusion. Abstracts were
eligible for inclusion if suHicient information was provided to judge
the quality and potential for bias of these trials.
Types of participants
Pregnant women with pre-existing diabetes mellitus (type 1 or type
2). Women with gestational diabetes mellitus (GDM) were excluded.
Types of interventions
Techniques of blood glucose monitoring including self-monitoring
of blood glucose (SMBG), continuous glucose monitoring (CGM) or
clinic monitoring. We also considered the timing and frequency of
monitoring.
Types of outcome measures
For this update, we used the Cochrane Pregnancy and Childbirth
core outcome set for reviews of diabetes in pregnancy, developed
by the Cochrane Pregnancy and Childbirth Australasian satellite.
Primary outcomes
Mother
1. Hypertensive disorders of pregnancy (including pre-eclampsia,
pregnancy-induced hypertension, eclampsia)
2. Caesarean section
Neonatal/infant
1. Large-for-gestational age
2. Perinatal mortality (stillbirth and neonatal mortality)
3. Mortality or morbidity composite
4. Neurosensory disability
Secondary outcomes
Mother
1. Induction of labour
2. Perineal trauma
3. Placental abruption
4. Postpartum haemorrhage
5. Postpartum infection
6. Weight gain during pregnancy
7. Adherence to the intervention
8. Behaviour changes associated with the intervention
9. Relevant biomarker changes associated with the intervention
(e.g. adiponectin, free fatty acids, triglycerides, high-density
lipoproteins, low-density lipoproteins, insulin)
10.Sense of well-being and quality of life
11.Views of the intervention
12.Breastfeeding (e.g. at discharge, six weeks postpartum)
13.Use of additional pharmacotherapy
14.Glycaemic control during/end of treatment (as defined by
trialists) (e.g. HbA1c, fructosamine, fasting blood glucose, post-
prandial blood glucose)
15.Maternal hypoglycaemia
16.Maternal mortality
17.Miscarriage
Long-term maternal outcomes
1. Postnatal depression
2. Postnatal weight retention or return to pre-pregnancy weight
3. Body mass index (BMI)
4. GDM in a subsequent pregnancy
5. Type 1 diabetes
6. Impaired glucose tolerance
7. Cardiovascular health (as defined by trialists, including blood
pressure, hypertension, cardiovascular disease, metabolic
syndrome)
Neonatal/infant
1. Stillbirth
2. Neonatal mortality
3. Gestational age at birth
4. Preterm birth (less than 37 weeks' gestation and less than 34
weeks' gestation)
5. Apgar score (less than seven at five minutes)
6. Macrosomia
7. Small-for-gestational age
8. Birthweight and z-score
9. Head circumference and z-score
10.Length and z-score
11.Ponderal index
12.Adiposity (e.g. BMI, skinfold thickness)
13.Shoulder dystocia
14.Bone fracture
15.Nerve palsy
16.Respiratory distress syndrome
17.Hypoglycaemia (variously defined)
18.Hyperbilirubinaemia
19.Neonatal hypocalcaemia
20.Polycythaemia
21.Relevant biomarker changes associated with the intervention
(e.g. cord c peptide, cord insulin)
22.Major and minor anomalies
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Later infant and childhood secondary outcomes
1. Weight and z scores
2. Height and z scores
3. Head circumference and z scores
4. Adiposity (e.g. as measured by BMI, skinfold thickness)
5. Blood pressure
6. Type 1 diabetes
7. Type 2 diabetes
8. Impaired glucose tolerance
9. Dyslipidaemia or metabolic syndrome
10.Educational achievement
Child in adulthood
1. Weight
2. Height
3. Adiposity (e.g. as measured by BMI, skinfold thickness)
4. Cardiovascular health (as defined by trialists, including blood
pressure, hypertension, cardiovascular disease, metabolic
syndrome)
5. Type 1 diabetes
6. Type 2 diabetes
7. Impaired glucose tolerance
8. Dyslipidaemia or metabolic syndrome
9. Employment, education and social status/achievement
Health service use
1. Number of hospital or health professional visits (e.g. midwife,
obstetrician, physician, dietician, diabetic nurse)
2. Number of antenatal visits or admissions
3. Length of antenatal stay
4. Neonatal intensive care unit admission
5. Length of postnatal stay (mother)
6. Length of postnatal stay (baby)
7. Costs to families associated with the management provided
8. Costs associated with the intervention
9. Cost of maternal care
10.Cost of oHspring care
Not pre-specified
1. Birth trauma (shoulder dystocia, bone fracture, nerve palsy) (not
pre-specified as a composite)
2. Neonatal glucose at age one hour
3. Transient tachypnoea
4. Diabetic ketoacidosis
5. Feeding diHiculties
Search methods for identification of studies
The following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (30 November 2016).
The Register is a database containing over 22,000 reports of
controlled trials in the field of pregnancy and childbirth. For full
search methods used to populate Pregnancy and Childbirth’s Trials
Register including the detailed search strategies for CENTRAL,
MEDLINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the editorial
information about the Cochrane Pregnancy and Childbirth in the
Cochrane Library and select the ‘Specialized Register ’ section from
the options on the leS side of the screen.
Briefly, the Cochrane Pregnancy and Childbirth’s Trials Register
is maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of Controlled
Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals plus
monthly BioMed Central email alerts.
Search results are screened by two people and the full text of
all relevant trial reports identified through the searching activities
described above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a
specific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Ongoing studies).
Searching other resources
Where studies could be accessed only as abstracts, we contacted
the study authors for more details. It was intended that these
trials would be included in the review if suHicient information was
provided to judge the quality and potential for bias of these trials.
We searched the reference lists of retrieved studies.
We did not apply any language or date restrictions.
Data collection and analysis
For methods used in the previous version of this review, see Moy
2014.
For this update, the following methods were used for assessing the
seven reports that were identified as a result of the updated search.
The following methods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies identified as a result of the search strategy. We
resolved any disagreement through discussion or, if required, we
consulted a third review author.
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Data extraction and management
We designed a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved
discrepancies through discussion or, if required, we consulted
a third review author. Data were entered into Review Manager
soSware (RevMan 2014) and checked for accuracy.
When information regarding any of the above was unclear, we
planned to contact authors of the original reports to provide further
details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for
each study using the criteria outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Any
disagreement was resolved by discussion or by involving a third
assessor.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in suHicient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random number
table; computer random number generator);• high risk of bias (any non-random process, e.g. odd or even date
of birth; hospital or clinic record number);• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias)
We described for each included study the method used to conceal
allocation to interventions prior to assignment and assessed
whether intervention allocation could have been foreseen in
advance of, or during recruitment, or changed aSer assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if they were blinded, or if we judged that the
lack of blinding was unlikely to aHect results. We assessed blinding
separately for diHerent outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for diHerent
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition
and exclusions from the analysis. We stated whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised participants),
reasons for attrition or exclusion where reported, and whether
missing data were balanced across groups or were related to
outcomes. Where suHicient information was reported, or could be
supplied by the trial authors, we planned to re-include missing data
in the analyses which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome
data balanced across groups);• high risk of bias (e.g. numbers or reasons for missing
data imbalanced across groups; ‘as treated’ analysis done
with substantial departure of intervention received from that
assigned at randomisation);• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it is clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review have been reported);• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);• unclear risk of bias.
(6) Other bias (checking for bias due to problems not covered by
(1) to (5) above)
We described for each included study any important concerns we
had about other possible sources of bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (Higgins
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2011). With reference to (1) to (6) above, we planned to assess
the likely magnitude and direction of the bias and whether we
considered it is likely to impact on the findings. In future updates,
we will explore the impact of the level of bias through undertaking
sensitivity analyses - see Sensitivity analysis.
Assessment of the quality of the evidence using the GRADE
approach
For this update the quality of the evidence was assessed using the
GRADE approach as outlined in the GRADE handbook in order to
assess the quality of the body of evidence relating to the following
outcomes for all comparisons.
1. Hypertensive disorders of pregnancy (pre-eclampsia,
gestational hypertension)
2. Caesarean section
3. Glycaemic control during/end of treatment (HbA1c, post-
prandial blood glucose)
4. Large-for-gestational age
5. Perinatal mortality
6. Preterm birth (less than 37 weeks' gestation and less than 34
weeks' gestation)
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention
eHect and a measure of quality for each of the above outcomes
was produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of eHect,
imprecision, indirectness and publication bias) to assess the
quality of the body of evidence for each outcome. The evidence can
be downgraded from 'high quality' by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of eHect estimates or potential publication bias.
Measures of treatment e;ect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
We used the mean diHerence if outcomes were measured in the
same way between trials. In future updates, if appropriate, we
will use the standardised mean diHerence to combine trials that
measure the same outcome, but use diHerent methods.
Unit of analysis issues
Trials with more than two intervention groups
Had we included trials with more than two techniques of glucose
monitoring, we planned to analyse them according to the methods
described in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011); the relevant pair of interventions
would have been selected and the others excluded.
Cluster-randomised trials
We did not identify any cluster-randomised trials for inclusion.
However, in future updates, if we identify any cluster-randomised
trials we will include them in the analyses along with individually-
randomised trials. We will adjust their sample sizes using the
methods described in the CochraneHandbook using an estimate
of the intracluster correlation co-eHicient (ICC) derived from the
trial (if possible), from a similar trial or from a study of a similar
population. If we use ICCs from other sources, we will report
this and conduct sensitivity analyses to investigate the eHect
of variation in the ICC. If we identify both cluster-randomised
trials and individually-randomised trials, we plan to synthesise the
relevant information. We will consider it reasonable to combine the
results from both if there is little heterogeneity between the study
designs and the interaction between the eHect of intervention and
the choice of randomisation unit is considered to be unlikely. We
will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the eHects of the
randomisation unit.
Dealing with missing data
For included studies, levels of attrition were noted. In future
updates, if more eligible studies are included, the impact of
including studies with high levels of missing data in the overall
assessment of treatment eHect will be explored by using sensitivity
analysis.
For all outcomes, analyses were carried out, as far as possible,
on an intention-to-treat basis, i.e. we attempted to include all
participants randomised to each group in the analyses. The
denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes were known
to be missing.
Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau2, I2 and Chi2 statistics. We regarded heterogeneity as
substantial if an I2 was greater than 30% and either a Tau2 was
greater than zero, or there was a low P value (less than 0.10)
in the Chi2 test for heterogeneity. Had we identified substantial
heterogeneity (above 30%), we planned to explore it by pre-
specified subgroup analysis.
Assessment of reporting biases
In future updates, if there are 10 or more studies in the meta-
analysis we will investigate reporting biases (such as publication
bias) using funnel plots. We will assess funnel plot asymmetry
visually. If asymmetry is suggested by a visual assessment, we will
perform exploratory analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager
soSware (RevMan 2014). We used fixed-eHect meta-analysis for
combining data where it was reasonable to assume that studies
were estimating the same underlying treatment eHect: i.e. where
trials were examining the same intervention, and the trials’
populations and methods were judged suHiciently similar.
If there was clinical heterogeneity suHicient to expect that
the underlying treatment eHects diHered between trials, or
if substantial statistical heterogeneity was detected, we used
random-eHects meta-analysis to produce an overall summary, if
an average treatment eHect across trials was considered clinically
meaningful. The random-eHects summary was treated as the
average range of possible treatment eHects and we discuss the
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clinical implications of treatment eHects diHering between trials.
If the average treatment eHect was not clinically meaningful, we
did not combine trials. Where we used random-eHects analyses,
the results are presented as the average treatment eHect with 95%
confidence intervals, and the estimates of Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
Had we identified substantial heterogeneity, we planned to
investigate it using subgroup analyses and to consider whether an
overall summary was meaningful, and if it was, to use a random-
eHects analysis to produce it.
We planned to restrict subgroup analyses to primary outcomes for
the following subgroups:
1. types of diabetes mellitus (type 1 versus type 2 diabetes);
2. glycaemic control prior to pregnancy (pre-pregnancy HbA1c
within target range versus pre-pregnancy HbA1c out of target
range).
However, we did not carry out any subgroup analysis as there
were too few trials included in any one comparison. Data for
outcomes in included trials were also not reported separately by
type of diabetes. Pre-pregnancy glycaemic control for all women
was comparable at baseline. These analyses will be conducted in
future updates of the review, if more data become available.
Sensitivity analysis
Sensitivity analysis was used to explore diHerences between fixed-
eHect or random-eHects analyses for outcomes with statistical
heterogeneity.
Sensitivity analysis was planned to assess the eHect on pooled
results of studies considered to have a high risk of bias. However,
due to the scarcity of data this analysis was not carried out. If
more data become available, the planned sensitivity analysis will
be carried out in future updates.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The updated search (30 November 2016) identified seven trial
reports in addition to the 21 trial reports identified in the original
search (6 August 2013). (See Figure 1 and Figure 2 for study flow
diagrams for the original search and updated search respectively).
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Figure 1.   Study flow diagram.
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Figure 2.   Study flow diagram 2016
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Of the seven reports in the updated search, five were additional
reports for previously identified studies (Bartholomew 2011; Feig
2012; Secher 2013), one previously ongoing study has been
included (Dalfrà 2009), and one study was excluded due to being a
cross-over trial (Bartholomew 2011).
There are now 10 studies (18 reports) included in the review (Dalfrà
2009; Di Biase 1997; Hanson 1984; Manderson 2003; Murphy 2008;
Petrovski 2011; Secher 2013; Stubbs 1980; Varner 1983; Wojcicki
2001, see Characteristics of included studies). Four trials have been
excluded (Bartholomew 2011; NCT01630759; Temple 2006; Walker
1999, see Characteristics of excluded studies), and two studies are
ongoing (Feig 2012; Voormolen 2012, see Characteristics of ongoing
studies).
Included studies
Three of the 10 included trials were from the UK (Manderson
2003; Murphy 2008; Stubbs 1980), two were from Italy (Dalfrà
2009; Di Biase 1997), and one each was from Sweden (Hanson
1984), Denmark (Secher 2013), Macedonia (Petrovski 2011), Poland
(Wojcicki 2001) and the USA (Varner 1983).
For full details, see Characteristics of included studies.
Participants
The trials included in this review involved a total of 538 women;
468 with type 1 diabetes and 70 with type 2 diabetes. Hanson 1984,
Murphy 2008 and Secher 2013 included women with pre-existing
type 1 and type 2 diabetes. Only women with pre-existing type 1
diabetes were eligible to participate in Di Biase 1997, Manderson
2003, Petrovski 2011, Stubbs 1980, Varner 1983, and Wojcicki 2001.
Women with pre-existing type 1 diabetes and gestational diabetes
participated in Dalfrà 2009, however the results are presented
separately so only data for women with type 1 diabetes are included
in this review. The ethnicity of the participants was not mentioned
in all trials. As these trials originated from the European countries
and the USA, it is assumed that majority of the participants were
white or Caucasians.
Intervention and comparison
Stubbs 1980 and Varner 1983 compared self-monitoring of blood
glucose (SMBG) with standard care, while Hanson 1984 compared
self-monitoring with hospitalisation. Manderson 2003 compared
timing of glucose monitoring, i.e. pre-prandial versus post-
prandial. Pre-prandial refers to measurement of blood glucose
before meals while post-prandial refers to blood glucose measured
two hours aSer a meal. Automated telemedicine monitoring versus
conventional system were compared in studies by Dalfrà 2009,
Di Biase 1997 and Wojcicki 2001. Continuous glucose monitoring
(CGM) was compared with intermittent glucose monitoring in
trials by Murphy 2008 and Secher 2013. Petrovski 2011 compared
constant CGM with intermittent CGM. Automated telemedicine
monitoring refers to automated transmission of blood glucose
values via telephone or internet to the physicians, which allows
immediate attention from the physicians. While CGM refers to
glucose measured in subcutaneous tissues every 10 seconds and
an average value is stored every five minutes, providing up to 288
measurements per day. As diHerent techniques or timing of glucose
monitoring were compared, blinding of neither participants nor
assessors was feasible. However, since outcome measures were
objective it is unlikely that lack of blinding introduced a risk of bias.
Outcomes
Primary outcomes were hypertensive disorders of pregnancy
(pre-eclampsia was reported by Hanson 1984; Manderson 2003;
Murphy 2008; Secher 2013, gestational hypertension was reported
by Hanson 1984), caesarean section (reported by Dalfrà 2009;
Hanson 1984; Manderson 2003; Murphy 2008; Petrovski 2011;
Secher 2013; Varner 1983), large-for-gestational age (reported by
Manderson 2003; Murphy 2008; Secher 2013, defined as birthweight
90th centile or above), perinatal mortality (reported by Hanson
1984; Manderson 2003; Murphy 2008; Varner 1983), neonatal
mortality or morbidity composite (reported by Dalfrà 2009;
Varner 1983), and neurosensory disability (not reported by any
trials).
Secondary maternal outcomes reported by the included studies
were placental abruption (reported by Hanson 1984), weight
gain during pregnancy (reported by Dalfrà 2009; Manderson
2003; Petrovski 2011), use of additional pharmacotherapy (use
of additional insulin therapy reported by Dalfrà 2009; insulin
dose reported by Di Biase 1997; Manderson 2003; Petrovski 2011),
glycaemic control during/end of treatment (HbA1c reported
by Dalfrà 2009; Di Biase 1997; Manderson 2003; Murphy 2008;
Petrovski 2011; Varner 1983; Wojcicki 2001; fasting blood glucose
reported by; post-prandial blood glucose reported by), maternal
hypoglycaemia (reported by Petrovski 2011) and miscarriage
(reported by Murphy 2008; Secher 2013; Varner 1983).
Secondary perinatal/neonatal outcomes reported by the included
studies were stillbirth (reported by Manderson 2003), neonatal
mortality (reported by Murphy 2008; Varner 1983), gestational
age at birth (reported by Dalfrà 2009; Di Biase 1997; Manderson
2003; Murphy 2008; Varner 1983; Wojcicki 2001), preterm birth
less than 37 weeks' gestation (reported by Hanson 1984;
Manderson 2003; Murphy 2008; Petrovski 2011; Secher 2013),
macrosomia (reported by Dalfrà 2009; Manderson 2003; Petrovski
2011, defined as birthweight greater than 4 kg in all three studies),
small-for-gestational age (reported by Murphy 2008 defined as
birthweight 10th centile or below), birthweight (reported by Dalfrà
2009; Manderson 2003; Murphy 2008; Stubbs 1980; Varner 1983),
adiposity (triceps skinfold thickness and subscapular skinfold
thickness reported by Manderson 2003), respiratory distress
syndrome (reported by Hanson 1984; Manderson 2003; Varner
1983), hypoglycaemia (reported by Hanson 1984; Manderson
2003; Murphy 2008; Petrovski 2011; Secher 2013; Varner 1983),
hyperbilirubinaemia (reported by Hanson 1984; Manderson 2003;
Varner 1983), neonatal hypocalcaemia (reported by Varner 1983),
polycythaemia (reported by Varner 1983), relevant biomarker
changes associated with the intervention (neonatal cord vein c-
peptide reported by Varner 1983, cord IGF-1 reported by Manderson
2003), and major anomalies (reported by Hanson 1984; Murphy
2008).
The only secondary health service use outcomes reported were
antenatal hospital admission (reported by Hanson 1984) and
neonatal intensive care admissions (reported by Manderson
2003; Murphy 2008).
Outcomes that were not pre-specified, but are reported in this
review are maternal diabetic ketoacidosis (reported by Petrovski
2011), birth trauma (shoulder dystocia, bone fracture and nerve
palsy, pre-specified as individual outcomes but reported as a
composite by Manderson 2003), neonatal glucose at age one hour
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(reported by Manderson 2003), transient tachypnoea (reported by
Manderson 2003), and feeding di;iculties (reported by Hanson
1984).
Secondary maternal outcomes not reported by any of the
included studies were: induction of labour, perineal trauma,
postpartum haemorrhage, postpartum infection, adherence to the
intervention, behaviour changes associated with the intervention,
relevant biomarker changes associated with the intervention
(e.g. adiponectin, free fatty acids, triglycerides, high-density
lipoproteins, low-density lipoproteins, insulin), sense of well-being
and quality of life, views of the intervention, maternal mortality.
Secondary perinatal/neonatal outcomes not reported by any of
the included studies were: preterm birth less than 34 weeks'
gestation, Apgar score (less than seven at five minutes) head
circumference and z-score, length and z-score, ponderal index,
adiposity measured by body mass index, and minor anomalies.
Health service use outcomes not reported by any of the included
studies were: health service use: number of hospital or health
professional visits (e.g. midwife, obstetrician, physician, dietician,
diabetic nurse), number of antenatal visits, length of antenatal stay,
length of postnatal stay (mother), length of postnatal stay (baby),
costs to families associated with the management provided, costs
associated with the intervention, cost of maternal care, and cost of
oHspring care.
No studies reported long-term maternal outcomes (postnatal
depression, postnatal weight retention or return to pre-
pregnancy weight, body mass index, impaired glucose tolerance,
cardiovascular health (as defined by trialists, including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome)), later infant or childhood outcomes (weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement), or child in adulthood outcomes (weight,
height, adiposity (e.g. as measured by body mass index, skinfold
thickness), cardiovascular health (as defined by trialists, including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome), type 1 diabetes, type 2 diabetes, impaired glucose
tolerance, dyslipidaemia or metabolic syndrome, employment,
education and social status/achievement).
Some outcomes were reported in a form that could not be used in
this review. Hanson 1984 reported the median antenatal hospital
stay and neonatal hospital stay, did not report the standard
deviation of blood glucose values, and only reported HbA1c
graphically. Manderson 2003 reported the median and interquartile
range for cord insulin and length of stay in neonatal unit, and
Secher 2013 reported weight gain in pregnancy, HbA1c, plasma
glucose, gestational age at birth, and birthweight as median
and range. Where results were reported as medians, we felt it was
unlikely that the results were normally distributed, and excluded
them from meta-analyses. Percentage of maternal hypoglycaemic
episodes was reported by Wojcicki 2001, however the total of all
blood glucose data were not available, therefore the frequency was
not estimable.
See the Characteristics of included studies table for more details.
Excluded studies
Bartholomew 2011 was excluded as it is a cross-over trial. Two
trial registrations (NCT01630759; Walker 1999) were excluded; the
former was a trial on women with gestational diabetes mellitus
(GDM) while the latter was a clinical trial registration containing
insuHicient evidence to assess. We contacted the author, but
there were no available data or published reports. Temple 2006
was excluded as it was an abstract on an observational study of
eight type 1 diabetic pregnant women using continuous glucose
monitoring system (CGMS).
See the Characteristics of excluded studies table for more details.
Risk of bias in included studies
One of the 10 included studies was at high risk of bias (Dalfrà 2009),
five studies were at moderate risk of bias (Hanson 1984; Manderson
2003; Petrovski 2011; Stubbs 1980; Varner 1983) and four studies
were at low to moderate risk of bias (Di Biase 1997; Murphy 2008;
Secher 2013; Wojcicki 2001). See Figure 3 and Figure 4.
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
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Figure 3.   (Continued)
 
 
Figure 4.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
 
Allocation
Random sequence generation
Only three studies (Murphy 2008; Secher 2013; Varner 1983)
described the random sequence generation using computer-
generated random numbers or random number sequence (low risk
of bias). Six trials (Di Biase 1997; Hanson 1984; Manderson 2003;
Petrovski 2011; Stubbs 1980; Wojcicki 2001) did not report how the
sequence was generated (unclear risk of bias). One study was quasi-
randomised, allocating women to alternating groups (Dalfrà 2009)
(high risk of bias).
Allocation concealment
Adequate and secure concealment of allocation was described in
three trials (low risk of bias) (Manderson 2003; Murphy 2008; Secher
2013), where sealed envelopes were used in the first two trials while
the third (Secher 2013) used an automated telephone allocation
service (Paravox) provided by an independent organisation. There
was no concealment of allocation in Wojcicki 2001 and Dalfrà 2009
(high risk of bias). The other trials only mentioned the participants
were randomly allocated into intervention or control groups
without describing if there was any concealment of allocation
(unclear risk of bias).
Blinding
There was no blinding in participants or outcome assessors in any
of the trials. As the participants were requested to use certain
technique of glucose monitoring by personnel taking care of them,
it was not feasible to blind either participants or outcome assessors.
However, as all outcome measures were objective, the lack of
blinding is unlikely to have eHected the outcomes (low risk of bias).
Incomplete outcome data
Four trials had high risk of bias for incomplete outcome data.
Reasons given for attrition were women not completing the
questionnaire (Dalfrà 2009), severe drug addiction, spontaneous
abortions and death of mother (Hanson 1984), no results
for analysis participants (Manderson 2003) and spontaneous
miscarriage (Varner 1983). In other included studies, all women
were accounted for in the analysis, or rates of attrition were
described (low risk of bias). Di Biase 1997 and Wojcicki 2001
reported all outcome data. Four trials reported using intention-to-
treat analysis (Murphy 2008; Petrovski 2011; Secher 2013; Stubbs
1980).
Selective reporting
It was unclear if there was any selective reporting in six trials
(Dalfrà 2009; Murphy 2008; Petrovski 2011; Secher 2013; Stubbs
1980; Varner 1983) (unclear risk of bias); the other four reported
all outcome data (Di Biase 1997; Hanson 1984; Manderson 2003;
Wojcicki 2001) (low risk of bias).
Other potential sources of bias
There were no other obvious potential sources of bias with the
exception of Dalfrà 2009, which did not use an intention-to-treat
analysis, and there was no sample size calculation, or information
on whether groups were comparable at baseline.
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E;ects of interventions
See: Summary of findings for the main comparison Self-
monitoring compared to standard care for women with pre-existing
diabetes; Summary of findings 2 Self-monitoring compared to
hospitalisation for women with pre-existing diabetes; Summary
of findings 3 Pre-prandial compared to post-prandial glucose
monitoring for women with pre-existing diabetes; Summary of
findings 4 Automated telemedicine monitoring compared to
conventional for women with pre-existing diabetes; Summary
of findings 5 Continuous glucose monitoring compared to
intermittent glucose monitoring for women with pre-existing
diabetes; Summary of findings 6 Constant CGM compared to
Intermittent CGM for women with pre-existing diabetes
As there were various methods of glucose monitoring being
implemented in the included trials, we used the following
comparisons.
1. Self-monitoring versus standard care
2. Self-monitoring versus hospitalisation
3. Pre-prandial versus post-prandial glucose monitoring
4. Automated telemedicine monitoring versus conventional
system
5. Continuous glucose monitoring (CGM) versus intermittent
monitoring
6. Constant CGM versus intermittent CGM
Comparison 1 - Self-monitoring versus standard care
See Summary of findings for the main comparison.
Two trials (Stubbs 1980; Varner 1983) compared self-monitoring
with standard care. In one trial (Stubbs 1980), a total of 13 type
1 diabetic (T1DM) pregnant women were randomly allocated into
self-monitoring of blood glucose (SMBG) at home, seven times a
day, twice per week. Another six women were allocated to standard
care (urine check four times daily) and random blood glucose
testing measured fortnightly during clinic visits.
In the other trial (Varner 1983), 30 T1DM women were assigned to
self-monitoring (n = 15) and standard care (n = 15). One woman in
each group had a first trimester spontaneous miscarriage, so results
are presented for the remaining 28 women and infants. The self-
monitoring group was required to monitor fasting plus two-hour
post-prandial morning, aSernoon and evening glucose daily, while
the standard care group were measured one day per week.
Primary outcomes
There was no clear diHerence in caesarean section (risk ratio
(RR) 0.78, 95% confidence interval (CI) 0.40 to 1.49, one study, 28
women, Analysis 1.1, very low-quality evidence). One study (Varner
1983) reported perinatal mortality and neonatal mortality and
morbidity composite, however it was too small to show any
diHerences between groups (perinatal mortality: RR 3.00, 95% CI
0.13 to 67.91, one study, 28 infants, very low-quality evidence,
Analysis 1.2; RR 3.00, 95% CI 0.13 to 67.91, one study, 28 infants,
Analysis 1.3).
Hypertensive disorders of pregnancy, large-for-gestational age
and neurosensory disability were not reported in either study.
Secondary outcomes
There was no clear diHerence in maternal glycaemic control
between self-monitoring and standard care for post-prandial
blood glucose (mean diHerence (MD) -0.70 mmol/L, 95% CI -2.15 to
0.75; one study, 13 women, Analysis 1.4, very low-quality evidence),
or HbA1c (MD -0.10 %, 95% CI -1.93 to 1.73, one study, 28
women, Analysis 1.5, very low-quality evidence). There were too
few participants to show any diHerences in miscarriage (RR 1.00,
95% CI 0.07 to 14.55, 30 women, one studyAnalysis 1.6), neonatal
mortality (RR 3.00, 95% CI 0.13 to 67.91, one study, 28 women,
Analysis 1.7) or respiratory distress syndrome (RR 3.00, 95% CI
0.13 to 67.91, one study, 28 infants, Analysis 1.10). There was no
clear diHerence in gestational age between self-monitoring and
standard care groups (MD 0.40 weeks, 95% CI -1.65 to 2.45, one
study, 28 infants, Analysis 1.8), and no clear diHerence in infant
birthweight (MD -0.18 kg, 95% CI -0.49 to 0.13, two studies, 41
infants, Analysis 1.9).
No clear diHerences were shown for neonatal hypoglycaemia (RR
0.57, 95% CI 0.21 to 1.52, one study, 28 infants, Analysis 1.11),
neonatal jaundice (hyperbilirubinaemia) (RR 0.56, 95% CI 0.25
to 1.24, one study, 28 infants, Analysis 1.12), hypocalcaemia (RR
1.00, 95% CI 0.07 to 14.45, one study, 28 infants, Analysis 1.13),
polycythaemia (RR 0.33, 95% CI 0.01 to 7.55, one study, 28 infants,
Analysis 1.14) and neonatal cord vein C-peptide (MD 0.13 ng/nl,
95% CI -0.50 to 0.76, one study, 28 infants, Analysis 1.15).
The following secondary outcomes were not reported.
Maternal: induction of labour, perineal trauma, placental
abruption, postpartum haemorrhage, postpartum infection,
weight gain during pregnancy, adherence to the intervention,
behaviour changes associated with the intervention, relevant
biomarker changes associated with the intervention (e.g.
adiponectin, free fatty acids, triglycerides, high-density
lipoproteins, low-density lipoproteins, insulin), sense of well-
being and quality of life, views of the intervention, breastfeeding
(e.g. at discharge, six weeks postpartum), use of additional
pharmacotherapy, maternal hypoglycaemia, maternal mortality.
Long-term maternal outcomes: postnatal depression, postnatal
weight retention or return to pre-pregnancy weight, body mass
index, type 1 diabetes, impaired glucose tolerance, cardiovascular
health (as defined by trialists, including blood pressure,
hypertension, cardiovascular disease, metabolic syndrome).
Neonatal/infant: stillbirth, preterm birth (less than 37 weeks'
gestation and less than 34 weeks' gestation), Apgar score (less
than seven at five minutes), macrosomia, small-for-gestational
age, head circumference and z-score, length and z-score, ponderal
index, adiposity (e.g. body mass index, skinfold thickness),
shoulder dystocia, bone fracture, nerve palsy, major and minor
anomalies.
Later infant and childhood secondary outcomes: weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement.
Child in adulthood: weight, height, adiposity (e.g. as measured
by body mass index, skinfold thickness), cardiovascular health
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(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome), type 1 diabetes, type
2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic
syndrome, employment, education and social status/achievement.
Health service use: number of hospital or health professional visits
(e.g. midwife, obstetrician, physician, dietician, diabetic nurse),
number of antenatal visits or admissions, length of antenatal
stay, neonatal intensive care unit admission, length of postnatal
stay (mother), length of postnatal stay (baby), costs to families
associated with the management provided, costs associated with
the intervention (e.g.), cost of maternal care, cost of oHspring care.
Comparison 2 - Self-monitoring versus hospitalisation
See Summary of findings 2.
Only one study compared home self-monitoring with
hospitalisation (Hanson 1984). In this study, a total of 100 T1DM
and T2DM pregnant women were randomised. The home self-
monitoring group had 54 women while the hospital group had 46
women. The women from the home group self-monitored their
blood glucose from the 32nd until 36th week of gestation and then
hospitalised during 37th week until delivery; the hospital group
women were hospitalised from 32nd week until delivery. Blood
glucose was monitored four times daily (7am, 9.30am, 3pm and
7pm) in both groups.
Primary outcomes
This study of 100 women reported hypertensive disorders of
pregnancy. There was no clear diHerence between self-monitoring
versus hospitalisation, however too few women experienced these
events to show any meaningful diHerences (pre-eclampsia: RR
4.26, 95% CI 0.52 to 35.16, Analysis 2.1, very low-quality evidence;
hypertension in pregnancy: RR 0.43, 95% CI 0.08 to 2.22, Analysis
2.2, very low-quality evidence).
There was no clear diHerence in caesarean section (RR 0.96, 95% CI
0.65 to 1.44, Analysis 2.3 very low-quality evidence), and the sample
size was too small to assess perinatal mortality (RR 0.85, 95% CI
0.05 to 13.24, Analysis 2.4, very low-quality evidence).
Large-for-gestational age, mortality or morbidity composite,
and neurosensory disability were not reported.
Secondary outcomes
No clear diHerences between self-monitoring and hospitalisation
were shown in the reported secondary outcomes: placental
abruption (RR 1.70, 95% CI 0.16 to 18.19, Analysis 2.5);preterm
birth < 37 weeks (RR 0.85, 95% CI 0.45 to 1.60, Analysis 2.6,
very low-quality evidence); respiratory distress syndrome (RR
2.56, 95% CI 0.28 to 23.74, Analysis 2.7); neonatal hypoglycaemia
(RR 1.01, 95% CI 0.50 to 2.03, Analysis 2.8); neonatal jaundice
(hyperbilirubinaemia) (RR 2.27, 95% CI 0.64 to 8.07, Analysis 2.9);
major anomalies (RR 0.27, 95% CI 0.03 to 2.54, Analysis 2.10).
As would be expected from the nature of the intervention, a lower
proportion of women in the self-monitoring group had antenatal
hospital admission (RR 0.19, 95% CI 0.11 to 0.33, Analysis 2.11).
Maternal glycaemic control was reported (Hanson 1984), however
only mean blood glucose was given without standard deviations,
and HbA1c was only presented graphically, so we were not able to
include these data in the analyses. The mean blood glucose values
during the study period were 6.0 mmol/L for the hospital group and
5.9 mmol/L for the home group.
Outcomes that were not pre-specified
No clear diHerences between self-monitoring and hospitalisation
were shown in feeding di;iculties (RR 0.85, 95% CI 0.41 to 1.78,
Analysis 2.12).
The following secondary outcomes were not reported.
Maternal: induction of labour, perineal trauma, postpartum
haemorrhage, postpartum infection, weight gain during
pregnancy, adherence to the intervention, behaviour changes
associated with the intervention, relevant biomarker changes
associated with the intervention (e.g. adiponectin, free fatty acids,
triglycerides, high-density lipoproteins, low-density lipoproteins,
insulin), sense of well-being and quality of life, views of
the intervention, breastfeeding (e.g. at discharge, six weeks
postpartum), use of additional pharmacotherapy, maternal
hypoglycaemia, maternal mortality, miscarriage, long-term
maternal outcomes, postnatal depression, postnatal weight
retention or return to pre-pregnancy weight, body mass index,
type 1 diabetes, impaired glucose tolerance, cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome).
Neonatal/infant: stillbirth, neonatal mortality, gestational age
at birth, preterm birth less than 34 weeks, Apgar score (less
than seven at five minutes), macrosomia, small-for-gestational
age, birthweight and z-score, head circumference and z-score,
length and z-score, ponderal index, adiposity (e.g. body mass
index, skinfold thickness), shoulder dystocia, bone fracture,
nerve palsy, neonatal hypocalcaemia, polycythaemia, relevant
biomarker changes associated with the intervention (e.g. cord c
peptide, cord insulin).
Later infant and childhood secondary outcomes: weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement.
Child in adulthood: weight, height, adiposity (e.g. as measured
by body mass index, skinfold thickness), cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome), type 1 diabetes, type
2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic
syndrome, employment, education and social status/achievement.
Health service use: number of hospital or health professional visits
(e.g. midwife, obstetrician, physician, dietician, diabetic nurse),
number of antenatal visits, length of antenatal stay, neonatal
intensive care unit admission, length of postnatal stay (mother),
length of postnatal stay (baby), costs to families associated with
the management provided, costs associated with the intervention
(e.g.), cost of maternal care, cost of oHspring care.
Comparison 3 - Pre-prandial versus post-prandial glucose
monitoring
See Summary of findings 3.
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Only one trial compared pre-prandial and post-prandial glucose
monitoring (Manderson 2003). Sixty-one T1DM women were
randomly assigned to pre-prandial (n = 31) or post-prandial (n = 30)
blood glucose monitoring. The pre-prandial group monitored their
blood glucose before breakfast and pre-prandially for each meal.
The post-prandial group monitored blood glucose before breakfast
and one hour aSer the commencement of each meal.
Primary outcomes
In one study of 61 women (61 infants), there was no clear diHerence
between pre-prandial and post-prandial glucose monitoring for
caesarean section (RR 1.45, 95% CI 0.92 to 2.28, Analysis 3.2, very
low-quality evidence and large-for-gestational age (RR 1.16, 95%
CI 0.73 to 1.85; Analysis 3.3, very low-quality evidence). The results
for hypertensive disorders of pregnancy: pre-eclampsia (RR
6.43, 95% CI 0.82 to 50.11, Analysis 3.1, very low-quality evidence)
and perinatal mortality (RR 2.91, 95% CI 0.12 to 68.66, Analysis
3.4, very low-quality evidence) are not meaningful because these
outcomes were too rare to show diHerences in a small sample.
The study did not report the outcomes mortality or morbidity
composite, or neurosensory disability.
Secondary outcomes
The study did not show a clear diHerence between pre-prandial and
post-prandial glucose monitoring for weight gain in pregnancy
(MD -0.90 kg, 95% CI -3.86 to 2.06, Analysis 3.5); use of additional
pharmacotherapy shown by insulin dose in units/day and units/
kg (MD -17.40 units/day, 95% CI -43.41 to 8.61, Analysis 3.6; MD
-0.20 units/kg, 95% CI -0.45 to 0.05, Analysis 3.7); glycaemic
control shown by mean HbA1c (MD 0.30 %, 95% CI -0.08 to
0.68, Analysis 3.8); stillbirth (RR 2.91, 95% CI 0.12 to 68.66,
Analysis 3.9); gestational age (MD 0.20 weeks, 95% CI -0.84 to
1.24, Analysis 3.10, very low-quality evidence); preterm birth < 37
weeks (RR 1.33, 95% CI 0.62 to 2.84, Analysis 3.11, very low-quality
evidence); macrosomia (RR 2.18, 95% CI 0.75 to 6.32, Analysis
3.12), birthweight (MD 0.24 kg, 95% CI -0.10 to 0.58, Analysis
3.13); subscapular skinfold thickness (adiposity) (MD 0.60 mm,
95% CI -0.18 to 1.38, Analysis 3.14); birth trauma (shoulder
dystocia, bone fracture, nerve palsy) (RR 0.48, 95% CI 0.05
to 5.06, Analysis 3.16); respiratory distress syndrome (RR 0.97,
95% CI 0.06 to 14.78, Analysis 3.17); neonatal hypoglycaemia
(RR 1.09, 95% CI 0.48 to 2.45, Analysis 3.18);neonatal jaundice
(hyperbilirubinaemia) (RR 1.16, 95% CI 0.40 to 3.40, Analysis 3.19);
Cord IGF-1 (MD 1.30 μg/L, 95% CI -0.70 to 3.30, Analysis 3.20);
neonatal glucose at age one hour (not pre-specified) (MD -0.20,
95% CI -0.88 to 0.48, Analysis 3.21); transient tachypnoea (not
pre-specified) (RR 2.58, 95% CI 0.76 to 8.81, Analysis 3.22); and
neonatal intensive care admissions (RR 1.04, 95% CI 0.62 to 1.74,
Analysis 3.23).
Infants in the pre-prandial monitoring group had higher triceps
skinfold thickness (adiposity) (MD 0.60 mm, 95% CI 0.04 to
1.16, Analysis 3.15) although the diHerence is small and should
be considered in the context of no clear diHerence in large-
for-gestational age, birthweight, macrosomia, and subscapular
skinfold thickness.
The following secondary outcomes were not reported.
Maternal: induction of labour, perineal trauma, placental
abruption, postpartum haemorrhage, postpartum infection,
adherence to the intervention, behaviour changes associated with
the intervention, relevant biomarker changes associated with
the intervention (e.g. adiponectin, free fatty acids, triglycerides,
high-density lipoproteins, low-density lipoproteins, insulin), sense
of well-being and quality of life, views of the intervention,
breastfeeding (e.g. at discharge, six weeks postpartum),
maternal hypoglycaemia, maternal mortality, miscarriage, long-
term maternal outcomes, postnatal depression, postnatal weight
retention or return to pre-pregnancy weight, body mass index,
type 1 diabetes, impaired glucose tolerance, cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome).
Neonatal/infant: neonatal mortality, preterm birth less than 34
weeks, Apgar score (less than seven at five minutes), small-for-
gestational age, head circumference and z-score, length and z-
score, ponderal index, neonatal hypocalcaemia, polycythaemia,
relevant biomarker changes associated with the intervention (e.g.
cord c peptide, cord insulin), major and minor anomalies.
Later infant and childhood secondary outcomes: weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement.
Child in adulthood: weight, height, adiposity (e.g. as measured
by body mass index, skinfold thickness), cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome), type 1 diabetes, type
2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic
syndrome, employment, education and social status/achievement.
Health service use: number of hospital or health professional visits
(e.g. midwife, obstetrician, physician, dietician, diabetic nurse),
number of antenatal visits or admissions, length of antenatal stay,
length of postnatal stay (mother), length of postnatal stay (baby),
costs to families associated with the management provided, costs
associated with the intervention (e.g.), cost of maternal care, cost
of oHspring care.
Comparison 4 - Automated telemedicine monitoring versus
conventional system
See Summary of findings 4.
Three studies (Dalfrà 2009; Di Biase 1997; Wojcicki 2001) compared
automated telemedicine monitoring versus conventional system.
Dalfrà 2009 included both women with type 1 diabetes (n = 32, data
included in this review) and women with gestational diabetes (n =
203, data excluded from this review). Women in the telemedicine
group were asked to submit their blood glucose data every week,
and had a medical examination at the diabetes clinic once a month,
while women in the control group had a medical examination
every two weeks. Di Biase 1997 (n = 20) and Wojcicki 2001 (n = 32)
recruited T1DM women. Di Biase 1997 used a DIANET system, which
was an automated monitoring system using a telemedicine system
with patient unit, diabetes workstation and the communication link
to send all data to the diabetologist. The intermittent monitoring
was conventional monitoring where the women were instructed
to perform three or more tests of blood glucose per day using
BM20-800 strips with the results checked during routine clinic
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visits. Wojcicki 2001 used a telematic management system with
the a glucometer connected to a modem interface where the
blood glucose measurements could be transmitted to the central
clinical control unit. The conventional group would only have their
measurements examined during the routine clinical examinations
every three weeks. All women (in both groups) were encouraged to
measure their blood glucose at least six times per day.
Primary outcomes
Dalfrà 2009 reported no clear diHerence between
automated telemedicine monitoring and conventional monitoring
forcaesarean section (RR 0.96, 95% CI 0.62 to 1.48, 32 women,
one study, Analysis 4.1, very low-quality evidence) and mortality or
morbidity composite (RR 1.18, 95% CI 0.53 to 2.62, 32 infants, one
study, Analysis 4.2).
Di Biase 1997 and Wojcicki 2001 did not report these primary
outcomes, and none of the studies contributing data to this
comparison reported hypertensive disorders of pregnancy,
large-for-gestational age, perinatal mortality (stillbirth and
neonatal mortality), and neurosensory disability.
Secondary outcomes
In one study of 20 women (Di Biase 1997), women in the automated
telemedicine group had a higher mean insulin requirement at
the end of the study (MD 18.40 units/day, 95% CI 12.88 to 23.92,
Analysis 4.5). The women in the automated telemedicine group also
had lower mean maternal fasting blood glucose before breakfast
and before lunch at the end of the study (before breakfast: MD
-1.00 mmol/L, 95% CI -1.22 to -0.78, Analysis 4.6; before lunch:
MD -1.10 mmol/L, 95% CI -1.32 to -0.88, Analysis 4.7). There was
high heterogeneity between studies for maternal HbA1c (random-
eHects MD -0.17 %, 95% CI -0.82 to 0.48, 82 women, three studies,
Tau2 = 0.27, I2 = 82%, Analysis 4.8, very low-quality evidence) and
maternal post-prandial blood glucose (random eHects MD -0.80
mmol/L, 95% CI -1.67 to 0.08, 50 women, three studies, Tau2 = 0.35,
I2 = 86%, Analysis 4.9, very low-quality evidence). Post hoc sensitivity
analyses show that this was due to measurements from Di Biase
1997. This study showed diHerences between groups in HbA1c and
post-prandial blood glucose, however the other two studies did
not. It seems likely that the higher insulin doses given to women in
the automated telemedicine group resulted in lower blood glucose
measures.
There was no clear diHerence between groups for: weight gain in
pregnancy (MD -0.70, 95% CI -4.95 to 3.55, 32 women, one study,
Analysis 4.3); use of additional insulin therapy (RR 1.00, 95% CI
0.89 to 1.12, 32 women, one study, Analysis 4.4); gestational age
(MD 0.13 weeks, 95% CI -0.14 to 0.39, 84 women, three studies,
Analysis 4.10); macrosomia (RR 1.18, 95% CI 0.31 to 4.43, 32 infants,
one study, Analysis 4.11); or birthweight (MD -0.16 kg, 95% CI -0.64
to 0.32, 32 infants, one study, Analysis 4.12).
Percentage of maternal hypoglycaemic episodes was reported by
Wojcicki 2001, however, the total of all blood glucose data were not
available, therefore the frequency was not estimable.
The following secondary outcomes were not reported.
Maternal: induction of labour, perineal trauma, placental
abruption, postpartum haemorrhage, postpartum infection,
adherence to the intervention, behaviour changes associated with
the intervention, relevant biomarker changes associated with
the intervention (e.g. adiponectin, free fatty acids, triglycerides,
high-density lipoproteins, low-density lipoproteins, insulin), sense
of well-being and quality of life, views of the intervention,
breastfeeding (e.g. at discharge, six weeks postpartum),
maternal hypoglycaemia, maternal mortality, miscarriage, long-
term maternal outcomes, postnatal depression, postnatal weight
retention or return to pre-pregnancy weight, body mass index,
type 1 diabetes, impaired glucose tolerance, cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome).
Neonatal/infant:stillbirth, neonatal mortality, preterm birth (less
than 37 weeks' gestation and less than 34 weeks' gestation),
Apgar score (less than seven at five minutes), small-for-
gestational age, head circumference and z-score, length and
z-score, ponderal index, adiposity (e.g. body mass index,
skinfold thickness), shoulder dystocia, bone fracture, nerve palsy,
respiratory distress syndrome, hypoglycaemia (variously defined),
hyperbilirubinaemia, neonatal hypocalcaemia, polycythaemia,
relevant biomarker changes associated with the intervention (e.g.
cord c peptide, cord insulin), major and minor anomalies.
Later infant and childhood secondary outcomes: weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement.
Child in adulthood: weight, height, adiposity (e.g. as measured
by body mass index, skinfold thickness), cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome), type 1 diabetes, type
2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic
syndrome, employment, education and social status/achievement.
Health service use: number of hospital or health professional visits
(e.g. midwife, obstetrician, physician, dietician, diabetic nurse),
number of antenatal visits or admissions, length of antenatal
stay, neonatal intensive care unit admission, length of postnatal
stay (mother), length of postnatal stay (baby), costs to families
associated with the management provided, costs associated with
the intervention, cost of maternal care, cost of oHspring care.
Comparison 5 - Continuous glucose monitoring (CGM) versus
intermittent monitoring
See Summary of findings 5.
Two studies compared CGM versus intermittent monitoring
(Murphy 2008; Secher 2013). The total number of women was 225
(169 T1DM and 56 T2DM). Secher 2013 contributed a large number
of participants in this comparison (n = 154).
Murphy 2008 used the CGMS, which measured glucose in
subcutaneous tissues every 10 seconds and an average value is
stored every five minutes, providing up to 288 measurements per
day (n = 38). The participants were required to wear the CGMS
for seven days at intervals of four to six weeks. They were also
advised to measure blood glucose at least seven times a day. The
intermittent monitoring of glucose levels was the standard care in
which participants were advised to monitor glucose at least seven
times a day (n = 33).
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In Secher 2013, real time CGM for six days at pregnancy visits during
eight, 12, 21, 27 and 33 weeks, in addition to routine pregnancy care
was implemented on 79 women and intermittent monitoring with
self-monitored plasma glucose measurements of seven times daily
was implemented on 75 women.
Primary outcomes
These studies showed no clear diHerence between groups for pre-
eclampsia (RR 1.37, 95% CI 0.52 to 3.59, 225 women, two studies,
Analysis 5.1, low-quality evidence). Due to high heterogeneity,
we used random-eHects analysis for caesarean section (average
RR 1.00, 95% CI 0.65 to 1.54, 255 women, two studies, Tau2 =
0.06, I2 = 62%, Analysis 5.2, very low-quality evidence) and large-
for-gestational age (average RR 0.89, 95% CI 0.41 to 1.92, 221
infants, two studies, Tau2 = 0.26, I2 = 82%, Analysis 5.3, very low-
quality evidence). There was no clear diHerence between groups for
these outcomes, and the eHects were in diHerent directions in the
two studies. There was not enough evidence to assess perinatal
mortality (RR 0.82, 95% CI 0.05 to 12.61, 71 infants, one study,
Analysis 5.4, low-quality evidence).
Mortality or morbidity composite and neurosensory disability
were not reported.
Secondary outcomes
Mean maternal HbA1c was lower for women in the continuous
monitoring group (MD -0.60 %, 95% CI -0.91 to -0.29, 71 women, one
study, moderate-quality evidence, Analysis 5.5).
No clear diHerence was shown between continuous glucose
monitoring and intermittent monitoring for miscarriage (RR 1.21,
95% CI 0.28 to 5.24, 228 women, two studies, Analysis 5.6), neonatal
mortality (RR 0.80, 95% CI 0.05 to 12.39, 74 infants, one study,
Analysis 5.7), gestational age (MD 0.10 weeks, 95% CI -0.57 to 0.77,
68 infants, one study, Analysis 5.8), preterm birth < 37 weeks
(RR 1.10, 95% CI 0.63 to 1.94, 228 infants, two studies, low-quality
evidence, Analysis 5.9), small-for-gestational age (RR 7.34, 95% CI
0.41 to 131.18, 67 infants, one study, Analysis 5.10), birthweight
(MD -0.29 kg, 95% CI -0.59 to 0.01, 67 infants, one study, Analysis
5.11), neonatal hypoglycaemia (RR 0.77, 95% CI 0.51 to 1.16, 228
infants, two studies, Analysis 5.12), major anomalies (RR 0.80, 95%
CI 0.05 to 12.39, 74 infants, one study, Analysis 5.13), and neonatal
intensive care admissions (RR 1.21, 95% CI 0.48 to 3.05, 74 infants,
one study, Analysis 5.14).
The following secondary outcomes were not reported.
Maternal: induction of labour, perineal trauma, placental
abruption, postpartum haemorrhage, postpartum infection,
weight gain during pregnancy, adherence to the intervention,
behaviour changes associated with the intervention, relevant
biomarker changes associated with the intervention (e.g.
adiponectin, free fatty acids, triglycerides, high-density
lipoproteins, low-density lipoproteins, insulin), sense of well-
being and quality of life, views of the intervention, breastfeeding
(e.g. at discharge, six weeks postpartum), use of additional
pharmacotherapy, maternal hypoglycaemia, maternal mortality,
long-term maternal outcomes, postnatal depression, postnatal
weight retention or return to pre-pregnancy weight, body mass
index, type 1 diabetes, impaired glucose tolerance, cardiovascular
health (as defined by trialists, including blood pressure,
hypertension, cardiovascular disease, metabolic syndrome).
Neonatal/infant:stillbirth, preterm birth less than 34 weeks, Apgar
score (less than seven at five minutes), macrosomia, head
circumference and z-score, length and z-score, ponderal index,
adiposity (e.g. body mass index, skinfold thickness), shoulder
dystocia, bone fracture, nerve palsy, respiratory distress syndrome,
hyperbilirubinaemia, neonatal hypocalcaemia, polycythaemia,
relevant biomarker changes associated with the intervention (e.g.
cord c peptide, cord insulin).
Later infant and childhood secondary outcomes: weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement.
Child in adulthood: weight, height, adiposity (e.g. as measured
by body mass index, skinfold thickness), cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome), type 1 diabetes, type
2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic
syndrome, employment, education and social status/achievement.
Health service use: number of hospital or health professional visits
(e.g. midwife, obstetrician, physician, dietician, diabetic nurse),
number of antenatal visits or admissions, length of antenatal stay,
length of postnatal stay (mother), length of postnatal stay (baby),
costs to families associated with the management provided, costs
associated with the intervention (e.g.), cost of maternal care, cost
of oHspring care.
Comparison 6 - Constant CGM versus intermittent CGM
See Summary of findings 6.
Only one study compared constant CGM and intermittent CGM
(Petrovski 2011). Twenty-five T1DM women were randomised into
constant CGM (n = 12) and intermittent CGM (n = 13) groups. The
women in the constant CGM group wore the glucose sensor 24
hours per day while the intermittent CGM group wore the glucose
sensor 14 days per month. The women in the intermittent CGM
group measured blood glucose at least six times daily when not
using the glucose sensor.
Primary outcomes
There was no clear diHerence between constant CGM and
intermittent CGM for caesarean section (RR 0.77, 95% CI 0.33
to 1.79, 25 women, one study, very low-quality evidence, Analysis
6.1). Other primary outcomes were not reported (hypertensive
disorders of pregnancy, large-for-gestational age, perinatal
mortality (stillbirth and neonatal mortality), mortality or
morbidity composite, and neurosensory disability).
Secondary outcomes
No clear diHerence was shown for weight gain in pregnancy
(MD 0.50 kg, 95% CI -1.82 to 2.82, 25 women, one study, Analysis
6.2),insulin dosage (third trimester: MD -0.03, 95% CI -1.30 to 1.24,
25 women, one study, Analysis 6.3); maternal blood glucose (first
trimester: MD -0.50 mmol/L, 95% CI -2.70 to 1.70, 25 women, one
study, Analysis 6.4; third trimester: MD -0.14 mmol/L, 95% CI -2.00
to 1.72, 25 women, one study, very low-quality evidence, Analysis
6.5); maternal HbA1c (first trimester: MD -0.30 %, 95% CI -1.13
to 0.53, 25 women, one study, Analysis 6.6; third trimester: MD
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-0.09 %, 95% CI -0.69 to 0.51, 25 women, one study, very low-
quality evidence Analysis 6.7), maternal hypoglycaemia (RR 0.54,
95% CI 0.06 to 5.24, 25 women, one study, Analysis 6.8), diabetic
ketoacidosis (not pre-specified) (RR 0.36, 95% CI 0.02 to 8.05, 25
women, one study, Analysis 6.9),preterm birth < 37 weeks (RR
1.08, 95% CI 0.08 to 15.46, 25 infants, one study, very low-quality
evidence Analysis 6.10), andmacrosomia (RR 1.08, 95% CI 0.08 to
15.46, 25 infants, one study, Analysis 6.11). There were no events for
neonatal hypoglycaemia (25 infants, one study, Analysis 6.12).
The following secondary outcomes were not reported.
Maternal: induction of labour, perineal trauma, placental
abruption, postpartum haemorrhage, postpartum infection,
adherence to the intervention, behaviour changes associated with
the intervention, relevant biomarker changes associated with
the intervention (e.g. adiponectin, free fatty acids, triglycerides,
high-density lipoproteins, low-density lipoproteins, insulin), sense
of well-being and quality of life, views of the intervention,
breastfeeding (e.g. at discharge, six weeks postpartum), maternal
mortality, miscarriage, long-term maternal outcomes, postnatal
depression, postnatal weight retention or return to pre-pregnancy
weight, body mass index, type 1 diabetes, impaired glucose
tolerance, cardiovascular health (as defined by trialists, including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome).
Neonatal/infant:stillbirth, neonatal mortality, gestational age at
birth, preterm birth less than 34 weeks' gestation, Apgar
score (less than seven at five minutes), small-for-gestational
age, birthweight and z-score, head circumference and z-score,
length and z-score, ponderal index, adiposity (e.g. body mass
index, skinfold thickness), shoulder dystocia, bone fracture,
nerve palsy, respiratory distress syndrome, hyperbilirubinaemia,
neonatal hypocalcaemia, polycythaemia, relevant biomarker
changes associated with the intervention (e.g. cord c peptide, cord
insulin), major and minor anomalies.
Later infant and childhood secondary outcomes: weight and z
scores, height and z scores, head circumference and z scores,
adiposity (e.g. as measured by body mass index, skinfold
thickness), blood pressure, type 1 diabetes, type 2 diabetes,
impaired glucose tolerance, dyslipidaemia or metabolic syndrome,
educational achievement.
Child in adulthood: weight, height, adiposity (e.g. as measured
by body mass index, skinfold thickness), cardiovascular health
(as defined by trialists, including blood pressure, hypertension,
cardiovascular disease, metabolic syndrome), type 1 diabetes, type
2 diabetes, impaired glucose tolerance, dyslipidaemia or metabolic
syndrome, employment, education and social status/achievement.
Health service use: number of hospital or health professional visits
(e.g. midwife, obstetrician, physician, dietician, diabetic nurse),
number of antenatal visits or admissions, length of antenatal
stay, neonatal intensive care unit admission, length of postnatal
stay (mother), length of postnatal stay (baby), costs to families
associated with the management provided, costs associated with
the intervention (e.g.), cost of maternal care, cost of oHspring care.
D I S C U S S I O N
Summary of main results
The objective of this review was to assess the various techniques of
glucose monitoring among pregnant women with pre-existing type
1 and type 2 diabetes. We included 10 trials comparing six diHerent
pairs of glucose monitoring techniques: self-monitoring versus
standard care (Stubbs 1980; Varner 1983), self-monitoring versus
hospitalisation (Hanson 1984), pre-prandial versus post-prandial
glucose monitoring (Manderson 2003), automated telemedicine
monitoring versus conventional (Dalfrà 2009; Di Biase 1997;
Wojcicki 2001), continuous glucose monitoring (CGM) versus
intermittent glucose monitoring (Secher 2013), and constant CGM
versus intermittent CGM (Petrovski 2011). The included trials
involved a total of 538 women (468 women with type 1 diabetes and
70 women with type 2 diabetes). All trials originated from European
countries and the USA.
Neither pooled analyses nor individual trial analyses showed
any clear advantages of one monitoring technique over another
for primary outcomes (hypertensive disorders of pregnancy,
caesarean section, perinatal mortality, neonatal morbidity and
mortality, and large-for-gestational age) and secondary outcomes
(such as maternal glycaemic control, preterm birth, frequency of
neonatal hypoglycaemia, and neonatal intensive care admission).
Many important outcomes were not reported, for example,
neurosensory disability and shoulder dystocia.
Self-monitoring versus standard care (two studies, 43 women):
there was no clear diHerence between groups for caesarean
section, or glycaemic control, and not enough evidence to assess
perinatal mortality and neonatal mortality and morbidity
composite. Hypertensive disorders of pregnancy, large-for-
gestational age, neurosensory disability andpreterm birth were
not reported in either study.
Self-monitoring versus hospitalisation (one study, 100 women):
there was no clear diHerence between groups for hypertensive
disorders of pregnancy (pre-eclampsia and hypertension in
pregnancy). There was no clear diHerence in caesarean section or
preterm birth less than 37 weeks, and the sample size was too
small to assess perinatal mortality. Large-for-gestational age,
mortality or morbidity composite, neurosensory disability and
preterm birth less than 34 weeks were not reported.
Pre-prandial versus post-prandial glucose monitoring (one study,
61 women): there was no clear diHerence between groups
for caesarean section, large-for-gestational age andglycaemic
control. The results for hypertensive disorders of pregnancy:
pre-eclampsia and perinatal mortality are not meaningful
because these outcomes were too rare to show diHerences in a
small sample. The study did not report the outcomes mortality or
morbidity composite, neurosensory disability orpreterm birth.
Automated telemedicine monitoring versus conventional system
(three studies, 84 women): there was no clear diHerence
between groups forcaesarean section, mortality or morbidity
composite and glycaemic control in the one study that reported
these outcomes. No studies reported hypertensive disorders
of pregnancy, large-for-gestational age, perinatal mortality
(stillbirth and neonatal mortality), neurosensory disability
orpreterm birth.
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CGM versus intermittent monitoring (two studies, 225 women):
there was no clear diHerence between groups for pre-eclampsia,
caesarean section, large-for-gestational age andpreterm birth
less than 37 weeks' gestation.Glycaemic control indicated
by mean maternal HbA1c was lower for women in the
continuous monitoring group. There was not enough evidence to
assess perinatal mortality. Mortality or morbidity composite,
neurosensory disability and preterm birth less than 34 weeks
were not reported.
Constant CGM versus intermittent CGM (one study, 25 women):
there was no clear diHerence between groups for caesarean
section, glycaemic control orpreterm birth less than 37 weeks'
gestation. Other primary (hypertensive disorders of pregnancy,
large-for-gestational age, perinatal mortality (stillbirth and
neonatal mortality), mortality or morbidity composite, and
neurosensory disability) or GRADE outcomes (preterm birth less
than 34 weeks' gestation) were not reported.
Overall completeness and applicability of evidence
There exists a shortage of evidence on the relative eHectiveness
of techniques of glucose monitoring among pregnant women
with pre-existing diabetes. The number of women allotted to
each technique was small and cannot be said to justify overall
completeness of evidence. Only 10 small trials were identified for
inclusion in the review. All the included trials were conducted in
Western countries - European and the USA - and it can be assumed
that a majority of the women were Caucasian. There were six
pairs of intervention techniques in the included trials. There was
diHiculty in pooling the results due to this variation. Evidence for
three comparisons came from single trial data (Comparisons 2, 3
and 6). The review's primary and secondary outcomes were not
reported by all trials. Birthweight was reported by six studies while
macrosomia (cut-oH value diHerent from this review) only reported
by one (Petrovski 2011). Some secondary outcomes, including
induction of labour, shoulder dystocia, major and minor anomalies
were not reported by any trials. Due to some older trials that
focused on non applicable clinical practice, small number of trials,
low to moderate risk of bias of the included trials and small
numbers of participants, the applicability of the current available
evidence is limited.
Quality of the evidence
Five of the ten included trials were at moderate risk of bias (Hanson
1984; Manderson 2003; Petrovski 2011; Stubbs 1980; Varner 1983).
Four trials (Di Biase 1997; Murphy 2008; Secher 2013; Wojcicki 2001)
were at low to moderate risk of bias. One trial was at high risk of bias
(Dalfrà 2009). Only three trials (Murphy 2008; Secher 2013; Varner
1983) described the random sequence generation while adequate
and secure concealment of allocation was described in three trials
(Manderson 2003; Murphy 2008; Secher 2013). It was unclear if there
was any selective reporting in six trials (Dalfrà 2009; Murphy 2008;
Petrovski 2011; Secher 2013; Stubbs 1980; Varner 1983), while the
other four reported all outcome data (Di Biase 1997; Hanson 1984;
Manderson 2003; Wojcicki 2001). However, most of the trials had
small numbers of participants; six trials (Dalfrà 2009; Di Biase 1997;
Petrovski 2011; Stubbs 1980; Varner 1983; Wojcicki 2001) only had
a range of 13 to 32 participants. Any potential bias is likely to have
been overshadowed by the small number and size of trials with
their diHerent intervention techniques of monitoring and reported
outcomes. The trials are too small to show diHerences in important
outcomes such as macrosomia, preterm birth, miscarriage or death
of baby.
All the reported GRADE outcomes for comparisons 1, 2, 3, 4 and
6 were assessed as being very low-quality evidence (Summary
of findings for the main comparison; Summary of findings 2;
Summary of findings 3; Summary of findings 4; Summary of
findings 6). This was due to design limitations in the studies, wide
confidence intervals crossing the line of no eHect, small sample
sizes, and few events. In addition, there was high heterogeneity
for glycaemic control (HbA1c and post-prandial blood glucose
measures) in comparison 4. Comparison 5 included more data
than the other comparisons (225 women), from studies with lower
risk of bias (Summary of findings 5). Consequently, glycaemic
control (HbA1c) was graded moderate-quality evidence, and pre-
eclampsia, perinatal mortality and preterm birth before 37 weeks
were graded low-quality evidence. Caesarean section and large-
for-gestational age were graded very low-quality evidence due to
statistical heterogeneity.
GRADE outcomes were oSen not reported. Caesarean section was
the only GRADE outcome reported by studies in every comparison.
Pre-eclampsia was not reported by any studies in comparisons 1,
4 and 6; gestational hypertension was not reported by any studies
in comparisons 1, 3, 4, 5 and 6; glycaemic control HbA1c was
not reported by any studies in comparison 2; glycaemic control
post-prandial blood glucose was not reported by any studies in
comparisons 2, 3 and 5; large-for-gestational age was not reported
by any studies in comparisons 1, 2, 4 and 6; perinatal mortality
was not reported by any studies in comparisons 4 and 6; and
preterm birth before 37 weeks was not reported by any studies in
comparisons 1 and 4.
Potential biases in the review process
With an extensive search without language restriction, we cannot
rule out the possibility that we have missed relevant studies that
were not published or are still ongoing. In addition, the proposed
subgroup and sensitivity analyses could not be performed.
Agreements and disagreements with other studies or
reviews
This review found no evidence that any glucose monitoring
techniques were superior over the other techniques among
pregnant women with pre-existing type 1 or type 2 diabetes. There
were no available reviews on self-monitoring of blood glucose
(SMBG) among pregnant women with pre-existing diabetes and so
the findings of this review cannot be compared with any other. This
review's findings are not altogether consistent with the findings
of others that considered methods for blood glucose monitoring
techniques amongst other diabetic populations. SMBG has been
found to be eHective for patients with type 1 diabetes (DCCT 1993)
and patients with type 2 diabetes who are using insulin (Karter
2001). One Cochrane review (Malanda 2012), concluded that SMBG
in newly diagnosed patients with type 2 diabetes who are not using
insulin is beneficial in lowering HbA1c. However, when the duration
of diabetes is over one year, the overall glycaemic eHects of SMBG
are small at short term and subside aSer one year.
Similar to the findings of this review, there is limited evidence for
the eHectiveness of real-time continuous glucose monitoring (CGM)
use in children, adults and patients with poorly controlled diabetes
Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
34
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
in one Cochrane review (Langendam 2012) and other reviews
(Ghandi 2011; Pickup 2011). However, these reviews indicated
that higher compliance of wearing the CGM device improves
glycosylated haemoglobin A1c level (HbA1c) to a larger extent.
Women with type 1 and type 2 diabetes are advised to self-monitor
their blood glucose throughout pregnancy (IDF 2010). The control
of hyperglycaemia in pregnant women with pre-existing diabetes
can reduce adverse maternal and infant outcomes (Kitzmiller 2008).
A Cochrane review has reported that pregnant women with type
1 or type 2 diabetes with tight to moderate glycaemic control had
significantly lower risks for pre-eclampsia, caesarean section and
macrosomia (Middleton 2016). However, the evidence base for the
relative eHectiveness of monitoring techniques is inconclusive.
Other than the above mentioned studies or reviews, we are not
aware of any other published reviews on techniques of glucose
monitoring among pregnant women with pre-existing diabetes.
There is a review on diHerent methods and settings for glucose
monitoring for gestational diabetes during pregnancy which is
currently being undertaken and due for publication in June 2017
(Gill 2014).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
This review found no evidence that any particular glucose
monitoring technique was superior over any other technique
among pregnant women with pre-existing type 1 or type 2 diabetes.
It is important to note that the results of this review were based
on 10 trials comparing six diHerent pairs of monitoring techniques.
Three comparisons were from single trial data. Until additional
evidence from large well-designed randomised trials becomes
available, current evidence is insuHicient on the eHectiveness of
any of the glucose monitoring techniques among pregnant women
with pre-existing diabetes.
Implications for research
More research is needed to identify the most eHective techniques of
blood glucose monitoring in pregnant women. Further larger trials
with suHicient power to assess the eHects of glucose monitoring
intervention techniques and monitoring on maternal and infant
health outcomes are indicated. Future studies should evaluate
women’s views of intervention techniques to see if benefits
outweigh harms, such as the inconveniences of invasive glucose
monitoring.
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Characteristics of included studies [ordered by study ID]
 
Methods Women were sequentially assigned to telemedicine and control groups (not randomised).
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Participants 88 women with gestational diabetes in the telemedicine group and 115 in the control group;
17 women with type 1 diabetes in the telemedicine group and 15 in the control group.
Inclusion criteria: pregnant women with type 1 diabetes (enrolled in the study at their first visit after
conception. Women with gestational diabetes included after a week from the diagnosis of gestational
diabetes.
Exclusion criteria: not described.
Interventions Intervention: automated telemedicine monitoring.
Control: conventional system.
Outcomes Pre-pregnancy BMI, week of gestation when diabetes was diagnosed (for gestational diabetes cases),
duration of diabetes (for type 1 cases), therapy, HbA1c at enrolment and at the end of pregnancy.
The maternal and fetal outcomes considered were: timing and mode of delivery, maternal complica-
tions (gestational hypertension, pre-eclampsia, eclampsia, hypoglycaemic episodes), and newborn’s
weight, presence of macrosomia (4000 g) and complications (e.g. hypoglycaemia, hyperbilirubinaemia,
respiratory distress syndrome, shoulder dystocia, malformations).
Notes Setting: 12 diabetes clinics.
Country: Italy.
Funding: not mentioned.
Comments: data for women with gestational diabetes and type 1 diabetes are presented separately.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk “Women were sequentially assigned to two groups: one patient was followed
up using the telemedicine approach and the next using the conventional ap-
proach (usual care).”
Allocation concealment
(selection bias)
High risk No attempt was made to conceal allocation.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk No attempt was made to blind women or personnel. Women were aware of
whether they were being monitored using telemedicine or usual care. Howev-
er, the outcomes were measured objectively and would not have been influ-
enced by blinding or not blinding.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No blinding of outcome assessment. However, all outcomes were objectively
measured.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 4/36 women with type 1 diabetes and 37/240 women with gestational diabetes
were excluded because they did not complete questionnaires at the end of the
study. It is unclear whether these were women with type 1 diabetes or gesta-
tional diabetes.
Selective reporting (re-
porting bias)
Unclear risk This study was assessed from a published report, without the study protocol.
The main outcomes were reported separately for type 1 diabetes and GDM,
however some outcomes were not reported separately or were only reported
in the text.
Other bias High risk The study did not use an intention-to-treat analysis. There is no sample size
calculation, or information on whether groups were comparable at baseline.
Dalfrà 2009  (Continued)
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Women with type 1 diabetes only make up a small part of the whole study (32
out of 235 women).
Dalfrà 2009  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: not mentioned.
Participants Number randomised: 20.
Eligible were type 1 diabetes mellitus (IDDM) pregnant patients attending the Diabetes Unit specialis-
ing in the treatment of diabetes in pregnancy during the period of study.
Inclusion criteria:
1. Type 1 DM pregnant patients.
Exclusion criteria:
1. Not mentioned in text.
Interventions Intervention:
DIANET system - continuous automated monitoring system using a telemedicine system - patient unit,
diabetes workstation and the communication link (n = 10).
Control:
Conventional monitoring - performed 3 or more tests of blood glucose per day using BM20-800 strips (n
= 10).
Outcomes Outcomes used in this review:
1) Mean blood glucose.
2) Occurence (weekly) of hypoglycaemic reactions.
Outcomes not used in this review:
1) Insulin requirement.
Notes Setting: Diabetes Unit specialising in the treatment of diabetes in pregnancy.
Country: Italy.
Funding: not mentioned.
Comments:
1. No sample size estimation reported.
2. No type 2 DM pregnant patients included.
3. Patients enrolled at 9.5 + 10 weeks, study ended at 37.6 + 0.4 weeks.
4. Hypoglycaemic episodes were graded in categories of 1 (mild) to 4 (severe).
5. Trial not registered ??
6. Therapeutic adjustment by the Diabetes Unit was performed every week by a visit to the control group.
7. The experimental group had their data stored in DIANET system transmitted to the team weekly. This
allowed feedback to both patients and clinicians.
Di Biase 1997 
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8. Clinic visit for experimental group is once every 15-30 days as they stayed at a longer distance from
the clinics than the control group.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from report - "Patients were consecutively chosen by 1 of the investiga-
tors. Stratified block randomisation was used to divide patients into 2 groups
at baseline." The patients were randomly assigned to a control of DIANET
group.
Comment - Methods of sequence allocation not stated.
Allocation concealment
(selection bias)
Unclear risk Comment - Not mentioned.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment - Reported results of all participants (n = 20).
Selective reporting (re-
porting bias)
Low risk As reported in the article all outcomes listed have been mentioned.
Other bias Low risk No obvious risk to other bias.
Di Biase 1997  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: 1 October 1979 - 1 October 1982.
Participants Number randomised: 100.
Eligible were type 1 diabetes mellitus (IDDM) and type 2 diabetes mellitus (NIDDM) pregnant patients
attending the from 5 hospitals in Stockholm during the period of study.
Inclusion criteria:
1. Patients with a diagnosis of diabetes, either insulin-dependent or non-insulin-dependent prior to
pregnancy.
Exclusion criteria:
1. Not mentioned in text.
Interventions Intervention:
Hanson 1984 
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Patients self-monitored their blood glucose at home from the 32nd week until the 36th week of gesta-
tion. Weekly hospital visit from 32-36 weeks and then hospitalised during the 37th week until delivery
(n = 54).
Control:
Patients were hospitalised from 32nd week until delivery (n = 46).
Outcomes Outcomes used in this review:
1) Mean blood glucose.
2) HbA1c.
3) Antenatal hospital stay (% requiring admission, length of stay).
4) Caesarean section rates.
5) Preterm birth.
6) Neonatal hypoglycaemia.
7) Perinatal death.
8) Neonatal hospital stay.
Outcomes not used in this review:
Maternal complications
1. Number of pregnancies.
2. Hypertenslon ln pregnancy.
3. Pre-eclampsia
4. Placenta praevia.
5. Abruptio placenta.
6. Pulmonary embolism.
7. Premature delivery (Induced, spontaneous).
Neonatal outcomes
1. Number of infants.
2. Major congenital malformations.
3. Respiratory distress syndrome.
4. Transient tachypnoea.
5. Hypoglycaemia, total.
6. Hypoglycaemia, symptomatic.
7. Hyperbilirubinemia.
8. Feeding problems.
9. Erythrocytosis.
Notes Setting: 5 hospitals in Stockholm.
Country: Sweden.
Funding: Expressens Perinatal forskningsfond, AIImanna Barnbordshusets Minnesfond, Svenska Di-
abetesstiftelsen, Nordisk Insulinfond, Swedish Medical Research Council (Project No. 3787), and Tiel-
man's Fund for Pediatric Research.
Comments:
1. No sample size estimation reported.
2. Twins were included (2 pairs).
Hanson 1984  (Continued)
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3. If complications occurred, home monitoring situation was interrupted.
4. The study was approved by the Regional Ethical Committee.
5. Informed consent was obtained from all participants.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment - Not mentioned.
Allocation concealment
(selection bias)
Unclear risk Comment - Not mentioned.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. Objective measurements
used.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Comment - 1 excluded for severe drug addiction, 8 spontaneous abortions and
1 mother died.
Selective reporting (re-
porting bias)
Low risk No obvious risk to selective reporting.
Other bias Low risk No obvious risk to other bias.
Hanson 1984  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: not mentioned.
Participants Number randomised: 61
Eligible were type 1 diabetes mellitus (IDDM) pregnant patients attending or referred to the Regional
Joint Metabolic/Antenatal Clinic at the Royal Maternity Hospital, Belfast during the period of study.
Inclusion criteria:
1. Type 1 DM pregnant women at 16 weeks' gestation.
Exclusion criteria:
1. Patients without results due to reasons like: stillbirth, abortions, major congenital abnormalities.
Interventions Intervention:
Pre-prandial glucose monitoring (n = 31).
Control:
Post-prandial glucose monitoring (n = 30).
Manderson 2003 
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Outcomes Outcomes used in this review:
1) Maternal glycaemic control (HbA1c, fasting blood glucose, post-prandial blood glucose, fruc-
tosamine).  
2) Birthweight.
3) Caesarean section rates.
4) Gestational age (at birth).
5) Frequency of neonatal hypoglycaemia.
6) Neonatal intensive care admissions.
7) Stillbirth.
Outcomes not used in this review:
1) Insulin dosage.
2) Pre-eclampsia.
3) Success in glycaemic control.
4) Compliance with schedule.
5) Birth trauma.
6) Cord Insulin.
7) Cord IGF-1.
8) Neonatal glucose at age 1 hour.
9) Triceps skinfold thickness.
10) Subscapula skinfold thickness.
Notes Setting: Regional Joint Metabolic/Antenatal Clinic at the Royal Maternity Hospital, Belfast.
Country: UK.
Funding: Department of Health and Social Sevices, Northern lreland, the Northern Ireland Mother and
Baby Appeal, the Metabolic Unit Research Fund, Royal Victoria Hospital, Belfast, the Royal Maternity
Hospital, Royal Victoria Hospital, Belfast, and the Irish Perinatal Society.
Comments:
1. No sample size estimation reported.
2. No type 2 DM pregnant patients included.
3. Only white women were included.
4. Patients were reviewed fortnightly or more frequently if clinically indicated.
5. Insulin doses were adjusted to achieve fasting glucose values between 60 mg/dL and 90 mg/dL (3.3
mmol/L and 5.0 mmol/L), pre-prandial values between 60 mg/dL and 105 mg/dL (3.3 mmol/L and 5.9
mmol/L), and post-prandial values less than 140 mg/dL (7.8 mmol/L).
6. Post-prandial glucose monitoring may significantly reduce the incidence of pre-eclampsia and neona-
tal triceps skinfold thickness compared with pre-prandial monitoring.
Risk of bias
Bias Authors' judgement Support for judgement
Manderson 2003  (Continued)
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Random sequence genera-
tion (selection bias)
Unclear risk Quote - "Women were randomly assigned at 16 weeks' gestation to 1 of 2
blood glucose monitoring protocols".
Comment - method not mentioned.
Allocation concealment
(selection bias)
Low risk Quote - "allocations were via a sealed envelope system, which the patient se-
lected from a box at the clinic visit".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Quote - "74 patients were recruited. 13 were excluded because they did not
have results for analysis. This leS 61 diabetic women (31 pre-prandial and 30
post-prandial monitoring) with results suitable for analysis".
Selective reporting (re-
porting bias)
Low risk No obvious risk to selective reporting.
Other bias Low risk No obvious risk to other bias.
Manderson 2003  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: September 2003-2006.
Participants Number randomised: 71.
Eligible were type 1 (IDDM) and type 2 (NIDDM) diabetes mellitus pregnant patients attending 2 sec-
ondary care diabetic antenatal clinics in the UK during the period of study.
Inclusion criteria:
1. Type 1 and type 2 DM pregnant women at 16 weeks' gestation.
2. Provided written informed consent.
3. Willing to wear a continuous glucose monitor.
Exclusion criteria:
1. Women with severe medical or psychological comorbidity.
Interventions Intervention:
Continuous glucose monitor which measured glucose in subcutaneous tissues every 10 seconds and an
average value is stored every 5 minutes, providing up to 288 measurements per day (n = 38). The partic-
ipants were required to wear the CGMS for 7 days at intervals of 4-6 weeks. They were also advised to
measure blood glucose at least 7 times a day.
Control:
Intermittent self-monitoring of glucose levels (n = 33), at least 7 times a day (standard care).
Murphy 2008 
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Outcomes Outcomes used in this review:
1) Maternal glycaemic control (HbA1c).
2) Birthweight.
3) Gestational age.
4) Frequency of maternal hypoglycaemia.
5) Caesarean section rates.
6) Frequency of neonatal hypoglycaemia.
7) Preterm birth.
8) Death of baby (stillbirth/neonatal death).
9) Neonatal intensive care admissions.
Outcomes not used in this review:
1) Number of women with pre-eclampsia.
2) Number of terminations.
3) Small-for-gestational age.
4) Macrosomia (more than 90th centile) - definition differ from the review.
Notes Setting: secondary care diabetic antenatal clinics.
Country: UK.
Funding: this was an investigator initiated study funded by the Ipswich Diabetes Centre Charity Re-
search Fund. HRM also received salary support from Diabetes UK. The study equipment (6 x CGMS Gold
monitors and 300 sensors) was donated free of charge by Medtronic UK. The research was sponsored
by Ipswich Hospital NHS Trust and was independent of all the study funders.
Comments:
1. Sample size estimation was reported.
2. Both type 1 and type 2 DM pregnant patients were included.
3. The women were predominantly white European.
4. The continuous glucose monitor (CGM) to be worn up to 7 days at intervals of 4-6 weeks between 8
and 32 weeks' gestation.
5. In addition to the CGM, intermittent self-monitoring of glucose levels was implemented in the inter-
vention group.
6. Therapeutic adjustments to diet, exercise, and insulin regimens were discussed with the obstetric
diabetes team, based on the combined intermittent capillary glucose and continuous glucose data
for women allocated to CGM or the intermittent capillary glucose data alone for women allocated to
standard antenatal care.
7. The women were advised to measure blood glucose levels at least 7 times a day and were provided
with several targets: 3.5 mmol/L to 5.5 mmol/L before meals, < 7.8 mmol/L 1 hour after meals, and <
6.7 mmol/L 2 hours after meals.
8. The women were seen every 2-4 weeks for up to 28 weeks, fortnightly until 32 weeks, and weekly
thereafter, with assessments of fetal growth at 28, 32, and 36 weeks.
9. Short-acting insulin analogues were used before meals with intermediate acting insulin, long-acting
analogues, or pump therapy. The women with type 2 diabetes were treated with insulin before preg-
nancy or as soon as pregnancy was confirmed.
10.Majority (90%) of women were White European, with the rest being Asian and others.
Murphy 2008  (Continued)
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote - "The study statistician used computer generated randomised numbers
in blocks of 20".
Allocation concealment
(selection bias)
Low risk Quote - "Concealed in sealed envelopes. Research nurses trained in accor-
dance with good clinical practice guidelines provided the women with their
group allocation".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment - Intention-to-treat analysis was applied.
Selective reporting (re-
porting bias)
Unclear risk Unclear.
Other bias Low risk No obvious risk to other bias.
Murphy 2008  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: not mentioned.
Participants Number randomised: 25.
Eligible were type 1 diabetes mellitus (IDDM) pregnant patients attending the University Clinic of En-
docrinology, Diabetes and Metabolic Disorders in Skopje during the period of study.
Inclusion criteria:
1. On continuous subcutaneous insulin infusion (CSII) for at least 3 months before conception.
2. Singleton pregnancy.
Exclusion criteria:
1. Not mentioned.
Interventions Intervention:
Constant CGM - 24 hours/day (n = 12).
Control:
Intermittent CGM - 14 days per month (n = 13), measured blood glucose at least 6 times a day every sec-
ond week (when not using the CGM).
Petrovski 2011 
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Outcomes Outcomes used in this review:
1) Maternal glycaemic control (HbA1c, mean blood glucose).
2) Severe hypoglycaemia (maternal).
3) Caesarean section rates.
4) Preterm birth.
5) Neonatal hypoglycaemia.
Outcomes not used in this review:
1) Birthweight greater than 4 kg - not used as macrosomia is defined as birthweight > 4.5k g.
2) Insulin dosage.
3) Weight gain.
4) Diabetic ketoacidosis.
Notes Setting: University Clinic of Endocrinology, Diabetes and Metabolic Disorders in Skopje.
Country: Macedonia.
Funding: Macedonion Ministry of Health and the Health Care Fund of Macedonia.
Comments:
1. No sample size estimation reported.
2. No type 2 DM pregnant patients included.
3. All patients were followed 1-3 weeks by a diabetologist and obstetrician.
4. The device could alert increased or decreased glucose levels, insulin pump was automatically suspend
insulin delivery if necessary.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote - "Patients were randomised into 2 groups".
Comment - Method not mentioned.
Allocation concealment
(selection bias)
Unclear risk Not mentioned.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intention-to-treat analysis.
Petrovski 2011  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Not mentioned.
Other bias Low risk No obvious risk to other bias.
Petrovski 2011  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: 15 February 2009 to 15 February 2011.
Participants Number randomised: 154.
Eligible were 123 type 1 (IDDM) and 31 type 2 (NIDDM) pregnant patients referred to the Centre for Preg-
nant Women with Diabetes, Rigshospitalet, before 14 completed gestational weeks.
Inclusion criteria:
1. Type 1 and type 2 DM pregnant women before 14 completed weeks of gestation.
2. Provided written informed consent.
3. Willing to wear a CGM.
Exclusion criteria:
1. Present use of real-time CGM.
2. Severe mental or psychiatric barriers.
3. Diabetic nephropathy.
4. Severe concurrent comorbidity (e.g. severe psoriasis, previous gastric bypass surgery).
Interventions Intervention:
Real time CGM for 6 days at pregnancy visits during 8, 12, 21, 27 and 33 weeks, in addition to routine
pregnancy care.
Control:
Routine pregnancy care with self-monitored plasma glucose measurements of 7 times daily.
Outcomes Outcomes used in this review:
1) Gycemic control (HbA1c, plasma glucose).
2) Live births.
3) Miscarriage.
4) Caeserean section.
5) Gestational age at birth.
6) Preterm delivery.
7) Birthweight.
8) Neonatal hypoglycaemia.
Outcomes not used in this review:
1) Weight gain in pregnancy.
Secher 2013 
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2) Pre-eclampsia.
3) Large-for-gestational age infant.
Notes Setting: Centre for Pregnant women with Diabetes, Rigshospitalet.
Country: Denmark.
Funding: the real-time CGM monitors and links were supplied, and glucose sensors were offered at a
reduced price by Medtronic.
Comments:
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote - "a computer generated randomization program was used".
Allocation concealment
(selection bias)
Low risk Quote - "..treatment allocation was properly concealed using automated tele-
phone allocation service (Paravox) provided by an independent organization".
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Quote - "Intention-to-treat analysis was carried out".
Selective reporting (re-
porting bias)
Unclear risk Not mentioned.
Other bias Low risk No obvious risk to other bias.
Secher 2013  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: not mentioned.
Participants Number randomised: 13.
Eligible were type 1 (IDDM) diabetes mellitus pregnant patients attending King College's Hospital.
Inclusion criteria:
1. Type 1 DM pregnant women at 30-31 weeks' gestation.
Exclusion criteria:
1. Not mentioned.
Stubbs 1980 
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Interventions Intervention:
1) Glucometer group (n = 7) measured blood glucose at home - 7 times a day, twice weekly (before and
after each main meal and before bedtime).
Control:
Non-meter group (n = 6) - checked urine glucose 4 times daily, random blood glucose measured at the
fortnightly clinic visits.
Outcomes Outcomes used in this review:
1) Maternal glycaemic control (post-prandial blood glucose).
2) Birthweight.
Outcomes not used in this review:
1) Blood metabolite (lactate, alanine, glycerol, 3-hydroxybutyrate).
Notes Setting: King's College hospital.
Country: UK.
Funding: Medical Research Council Project Grant and the British Diabetic Association.
Comments:
1. Sample size estimation was not reported.
2. Type 2 DM pregnant patients were not included.
3. A third group (normal women, n = 8) was included for comparison.
4. The women were at 30-31 weeks' gestation at the beginning of study.
5. Women in the intervention group had their diet and insulin dosage adjusted by telephone or clinic
consultation.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Comment - not mentioned.
Allocation concealment
(selection bias)
Unclear risk Comment - not mentioned.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Comment - intention-to-treat.
Selective reporting (re-
porting bias)
Unclear risk Not mentioned.
Stubbs 1980  (Continued)
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Other bias Low risk No obvious risk to other bias.
Stubbs 1980  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: 1 February 1980 to 16 September 1981.
Participants Number randomised: 30.
Eligible were type 1 diabetes mellitus (IDDM) pregnant patients attending the High Risk Obstetric Clinic
at the University of Iowa Hospitals and Clinics during the period of study.
Inclusion criteria:
1. Less than 20 weeks' gestation.
Exclusion criteria:
1. Not mentioned.
Interventions Intervention:
Daily home glucose monitoring (n = 15) - fasting, 2-hour post-prandial morning, afternoon and evening
glucose values were measured daily.
Control:
Weekly venipuncture (n = 15) - fasting, 2 hours after breakfast, and 2 hours after lunch glucose levels
measured on 1 day each week.
Outcomes Outcomes used in this review:
1) Maternal glycaemic control (HbA1c).
2) Birthweight.
3) Caesarean section.
4) Gestational age.
Outcomes not used in this review:
1) Cord vein C-peptide.
Notes Setting: High Risk Obstetric Clinic at the University of Iowa Hospitals and Clinics, Iowa.
Country: USA.
Funding: Research Fellowship from the Iowa Affiliate of the American Diabetes Association.
Comments:
1. No sample size estimation reported.
2. No type 2 DM pregnant patients included.
3. Patients telephoned their physicians weekly to report their blood glucose values or possible compli-
cations.
4. Insulin was adjusted by the patients with physicians' consultation.
Risk of bias
Varner 1983 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote - "Patients were assigned to control and experimental groups using a
random number sequence".
Allocation concealment
(selection bias)
Unclear risk Comment - Not mentioned.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of outcome assessment. However, all outcomes were
objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 2 patients from each group had a first trimester spontaneous miscarriage and
were excluded (2 out of 30 = 7%).
Selective reporting (re-
porting bias)
Unclear risk Not mentioned.
Other bias Low risk No obvious risk to other bias.
Varner 1983  (Continued)
 
 
Methods Randomised, parallel-group, open-label, 2-armed, active controlled trial.
Period of study: not mentioned.
Participants Number randomised: 32.
Eligible were type 1 diabetes mellitus (IDDM) pregnant patients attending the Clinic of Gastroenterolo-
gy and Metabolic Diseases of the Medical Academy in Warsaw during the period of study.
Inclusion criteria:
1. Duration of pregnancy less than 16 weeks.
2. No diseases.
3. Acceptable intelligence level according to the modified Wechsler-Bellevue Scale for Adults.
4. Glycaemic control in the range of HbA1c < 9.5%.
Exclusion criteria:
1. Not mentioned.
Interventions Intervention:
Telematic Management System (Central Clinical Unit and Patients' Teletransmission Modules) (n = 15) -
daily transfer of glycaemic data to diabetologist, at least 6 blood glucose measurements daily.
Control:
Standard care without Telematic Management System (n = 15), 6 blood glucose measurement daily
and routine clinic visit every 3 weeks.
Wojcicki 2001 
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Outcomes Outcomes used in this review:
1) Maternal glycaemic control (HbA1c, mean blood glucose).  
2) Hypoglycaemia (maternal).
Outcomes not used in this review:
1) Hyperglycaemia (maternal).
Notes Setting: Clinic of Gastroenterology and Metabolic Diseases of the Medical Academy in Warsaw.
Country: Poland.
Funding: not mentioned.
Comments:
1. No sample size estimation reported.
2. No type 2 DM pregnant patients included.
3. 2 participants in the intervention group were excluded as they had pneumonia and Meniere's disease
not diagnosed before randomisation.
4. Intensive insulin treatment was provided with multi-injection technique with 6 blood glucose mea-
surements per day (before and 60 minutes after the 3 main meals).
5. Each patient was followed up every 3 weeks by the same diabetologist.
6. Patients from the intervention group had their blood glucose data transmitted to the diabetologist
daily. Thus the diabetologist was able to examine the metabolic state and to intervene if necessary.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Randomisation stated but method of sequence generation not clear "Before
randomization written consent was taken........".
Allocation concealment
(selection bias)
High risk Not possible as the same diabetologist was seeing both groups and knew to
which group the participant belonged (control group could access the dia-
betologist by phone any time).
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, this may not
affect the results as all outcomes were objectively measured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Comment - No blinding of participants and personnel. However, all outcomes
were objectively measured.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk All participants accounted for and all data reported.
Selective reporting (re-
porting bias)
Low risk No obvious risk to selective reporting.
Other bias Low risk No obvious risk to other bias.
Wojcicki 2001  (Continued)
BMI: body mass index
CGM: continuous glucose monitoring
Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
55
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
CGMS: continuous glucose monitoring system
DM: diabetes mellitus
GDM: gestational diabetes mellitus
IDDM: insulin-dependent diabetes mellitus
IGF-1: insulin-like growth factor-1
NIDDM: non insulin-dependent diabetes mellitus
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Bartholomew 2011 Cross-over trial. Included women with GDM AND pre-existing type 2 diabetes: results are not pre-
sented separately.
NCT01630759 Clinical trial registration - for gestational diabetics only - started in January 2012, expected to com-
plete by April 2013.
Temple 2006 Abstract of an observational study of 8 type 1 diabetic pregnant women using CGMS.
Walker 1999 Clinical trial registration - contacted author, no published data or report available.
CGMS: continuous glucose monitoring system
GDM: gestational diabetes mellitus
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Continuous glucose monitoring in women with type 1 diabetes in pregnancy trial (CONCEPTT).
Methods Open-label, parallel, 2-arm, randomised controlled trial.
Participants Type 1 diabetic pregnant women.
Interventions Real time CGM versus home glucose monitoring (standard care).
Outcomes HbA1c, pre-eclampsia, caesarean sections, gestational weight gain, incidence of clinical events,
hospital admission, birthweight, pregnancy loss (miscarriage, still birth, neonatal death), preterm
delivery, birth injury, shoulder dystocia, neonatal hypoglycaemia, neonatal intensive care unit ad-
mission, etc.
Starting date March 2013.
Contact information Sonya Mergler, 416-480-5627, Email: conceptt@sunnybrook.ca
Notes Expected to complete by December 2015.
Feig 2012 
 
 
Trial name or title Effectiveness of continuous glucose monitoring during diabetic pregnancy (GlucoMOMS trial); a
randomised controlled trial.
Methods Multicentre open-label randomised controlled trial.
Participants Type 1 or type 2 diabetics pregnant women, gestational diabetic women.
Voormolen 2012 
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Interventions CGM with standard care versus standard care.
Outcomes Macrosomia, birthweight, composite neonatal morbidity, maternal outcome and costs.
Starting date July 2011.
Contact information Munster, van; +31 (0)88 7555555, Email: GlucoMOMS@studies-obsgyn.nl
Notes Expected to complete by July 2014. In September 2015 (Evers 2016) type 1 DM n = 109, type 2 DM n
= 83, GDM n = 108.
Voormolen 2012  (Continued)
CGM: continuous glucose monitoring
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Self-monitoring versus standard care
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Caesarean section 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.40, 1.49]
2 Perinatal mortality 1 28 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.91]
3 Neonatal mortality and morbidity
composite
1 28 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.91]
4 Glycaemic control during/end of
treatment (maternal post-prandial
blood glucose)
1 13 Mean Difference (IV, Fixed, 95% CI) -0.70 [-2.15, 0.75]
5 Glycaemic control during/end of
treatment (maternal HbA1c)
1 28 Mean Difference (IV, Fixed, 95% CI) -0.10 [-1.93, 1.73]
6 Miscarriage 1 30 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.55]
7 Neonatal mortality 1 28 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.91]
8 Gestational age at birth 1 28 Mean Difference (IV, Fixed, 95% CI) 0.40 [-1.65, 2.45]
9 Birthweight 2 41 Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.49, 0.13]
10 Respiratory distress syndrome 1 28 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.91]
11 Neonatal hypoglycaemia 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.21, 1.52]
12 Neonatal jaundice (hyperbilirubi-
naemia)
1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.25, 1.24]
13 Neonatal hypocalcaemia 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.45]
14 Neonatal polycythaemia 1 28 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.55]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
15 Neonatal cord vein C-peptide 1 28 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.50, 0.76]
 
 
Analysis 1.1.   Comparison 1 Self-monitoring versus standard care, Outcome 1 Caesarean section.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 7/14 9/14 100% 0.78[0.4,1.49]
   
Total (95% CI) 14 14 100% 0.78[0.4,1.49]
Total events: 7 (Self monitoring), 9 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.75(P=0.45)  
Favours self-monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.2.   Comparison 1 Self-monitoring versus standard care, Outcome 2 Perinatal mortality.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 1/14 0/14 100% 3[0.13,67.91]
   
Total (95% CI) 14 14 100% 3[0.13,67.91]
Total events: 1 (Self monitoring), 0 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.3.   Comparison 1 Self-monitoring versus standard
care, Outcome 3 Neonatal mortality and morbidity composite.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 1/14 0/14 100% 3[0.13,67.91]
   
Total (95% CI) 14 14 100% 3[0.13,67.91]
Total events: 1 (Self monitoring), 0 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
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Analysis 1.4.   Comparison 1 Self-monitoring versus standard care, Outcome 4
Glycaemic control during/end of treatment (maternal post-prandial blood glucose).
Study or subgroup Self monitoring Standard
care (urine)
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Stubbs 1980 7 4.6 (1.1) 6 5.3 (1.5) 100% -0.7[-2.15,0.75]
   
Total *** 7   6   100% -0.7[-2.15,0.75]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.95(P=0.34)  
Favours self-monitoring 42-4 -2 0 Favours standard care
 
 
Analysis 1.5.   Comparison 1 Self-monitoring versus standard care,
Outcome 5 Glycaemic control during/end of treatment (maternal HbA1c).
Study or subgroup Self monitoring Standard
care (urine)
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Varner 1983 14 7.1 (2.1) 14 7.2 (2.8) 100% -0.1[-1.93,1.73]
   
Total *** 14   14   100% -0.1[-1.93,1.73]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.11(P=0.91)  
Favours self monitoring 52.5-5 -2.5 0 Favours standard care
 
 
Analysis 1.6.   Comparison 1 Self-monitoring versus standard care, Outcome 6 Miscarriage.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 1/15 1/15 100% 1[0.07,14.55]
   
Total (95% CI) 15 15 100% 1[0.07,14.55]
Total events: 1 (Self monitoring), 1 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours self-monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.7.   Comparison 1 Self-monitoring versus standard care, Outcome 7 Neonatal mortality.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 1/14 0/14 100% 3[0.13,67.91]
   
Total (95% CI) 14 14 100% 3[0.13,67.91]
Total events: 1 (Self monitoring), 0 (Standard care (urine))  
Favours self monitoring 1000.01 100.1 1 Favours standard care
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Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.8.   Comparison 1 Self-monitoring versus standard care, Outcome 8 Gestational age at birth.
Study or subgroup Self monitoring Standard
care (urine)
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Varner 1983 14 38 (3.1) 14 37.6 (2.4) 100% 0.4[-1.65,2.45]
   
Total *** 14   14   100% 0.4[-1.65,2.45]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.7)  
Favours standard care 52.5-5 -2.5 0 Favours self-monitoring
 
 
Analysis 1.9.   Comparison 1 Self-monitoring versus standard care, Outcome 9 Birthweight.
Study or subgroup Self monitoring Standard
care (urine)
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Stubbs 1980 7 3.3 (0.6) 6 3.4 (0.6) 22.54% -0.14[-0.8,0.52]
Varner 1983 14 3 (0.5) 14 3.2 (0.5) 77.46% -0.19[-0.55,0.17]
   
Total *** 21   20   100% -0.18[-0.49,0.13]
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=1.12(P=0.26)  
Favours self-monitoring 21-2 -1 0 Favours control
 
 
Analysis 1.10.   Comparison 1 Self-monitoring versus standard care, Outcome 10 Respiratory distress syndrome.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 1/14 0/14 100% 3[0.13,67.91]
   
Total (95% CI) 14 14 100% 3[0.13,67.91]
Total events: 1 (Self monitoring), 0 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
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Analysis 1.11.   Comparison 1 Self-monitoring versus standard care, Outcome 11 Neonatal hypoglycaemia.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 4/14 7/14 100% 0.57[0.21,1.52]
   
Total (95% CI) 14 14 100% 0.57[0.21,1.52]
Total events: 4 (Self monitoring), 7 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.12(P=0.26)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.12.   Comparison 1 Self-monitoring versus standard
care, Outcome 12 Neonatal jaundice (hyperbilirubinaemia).
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 5/14 9/14 100% 0.56[0.25,1.24]
   
Total (95% CI) 14 14 100% 0.56[0.25,1.24]
Total events: 5 (Self monitoring), 9 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.13.   Comparison 1 Self-monitoring versus standard care, Outcome 13 Neonatal hypocalcaemia.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 1/14 1/14 100% 1[0.07,14.45]
   
Total (95% CI) 14 14 100% 1[0.07,14.45]
Total events: 1 (Self monitoring), 1 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours self monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.14.   Comparison 1 Self-monitoring versus standard care, Outcome 14 Neonatal polycythaemia.
Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Varner 1983 0/14 1/14 100% 0.33[0.01,7.55]
   
Total (95% CI) 14 14 100% 0.33[0.01,7.55]
Favours self monitoring 1000.01 100.1 1 Favours standard care
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Study or subgroup Self monitoring Standard
care (urine)
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 0 (Self monitoring), 1 (Standard care (urine))  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.69(P=0.49)  
Favours self monitoring 1000.01 100.1 1 Favours standard care
 
 
Analysis 1.15.   Comparison 1 Self-monitoring versus standard care, Outcome 15 Neonatal cord vein C-peptide.
Study or subgroup Self monitoring Standard
care (urine)
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Varner 1983 14 1.1 (0.8) 14 0.9 (0.9) 100% 0.13[-0.5,0.76]
   
Total *** 14   14   100% 0.13[-0.5,0.76]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Favours self monitoring 21-2 -1 0 Favours standard care
 
 
Comparison 2.   Self-monitoring versus hospitalisation
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pre-eclampsia 1 100 Risk Ratio (M-H, Fixed, 95% CI) 4.26 [0.52, 35.16]
2 Hypertension in pregnancy 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.08, 2.22]
3 Caesarean section 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.65, 1.44]
4 Perinatal mortality 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.05, 13.24]
5 Placental abruption 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [0.16, 18.19]
6 Preterm birth < 37 weeks 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.45, 1.60]
7 Respiratory distress syndrome 1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.28, 23.74]
8 Neonatal hypoglycaemia 1 100 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.50, 2.03]
9 Neonatal jaundice (hyperbilirubi-
naemia)
1 100 Risk Ratio (M-H, Fixed, 95% CI) 2.27 [0.64, 8.07]
10 Major anomalies 1 102 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.03, 2.54]
11 Antenatal hospital admission 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.11, 0.33]
12 Feeding difficulties (not pre-specified) 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.41, 1.78]
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Analysis 2.1.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 1 Pre-eclampsia.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 5/54 1/46 100% 4.26[0.52,35.16]
   
Total (95% CI) 54 46 100% 4.26[0.52,35.16]
Total events: 5 (Self-monitoring), 1 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.35(P=0.18)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.2.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 2 Hypertension in pregnancy.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 2/54 4/46 100% 0.43[0.08,2.22]
   
Total (95% CI) 54 46 100% 0.43[0.08,2.22]
Total events: 2 (Self-monitoring), 4 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.01(P=0.31)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.3.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 3 Caesarean section.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 26/54 23/46 100% 0.96[0.65,1.44]
   
Total (95% CI) 54 46 100% 0.96[0.65,1.44]
Total events: 26 (Self-monitoring), 23 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.18(P=0.85)  
Favours self-monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.4.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 4 Perinatal mortality.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 1/54 1/46 100% 0.85[0.05,13.24]
   
Total (95% CI) 54 46 100% 0.85[0.05,13.24]
Total events: 1 (Self-monitoring), 1 (Hospitalisation)  
Heterogeneity: Not applicable  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
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Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=0.11(P=0.91)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.5.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 5 Placental abruption.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 2/54 1/46 100% 1.7[0.16,18.19]
   
Total (95% CI) 54 46 100% 1.7[0.16,18.19]
Total events: 2 (Self-monitoring), 1 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.44(P=0.66)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.6.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 6 Preterm birth < 37 weeks.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 14/54 14/46 100% 0.85[0.45,1.6]
   
Total (95% CI) 54 46 100% 0.85[0.45,1.6]
Total events: 14 (Self-monitoring), 14 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.5(P=0.62)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.7.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 7 Respiratory distress syndrome.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 3/54 1/46 100% 2.56[0.28,23.74]
   
Total (95% CI) 54 46 100% 2.56[0.28,23.74]
Total events: 3 (Self-monitoring), 1 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.83(P=0.41)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
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Analysis 2.8.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 8 Neonatal hypoglycaemia.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 13/54 11/46 100% 1.01[0.5,2.03]
   
Total (95% CI) 54 46 100% 1.01[0.5,2.03]
Total events: 13 (Self-monitoring), 11 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.99)  
Favours self-monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.9.   Comparison 2 Self-monitoring versus hospitalisation,
Outcome 9 Neonatal jaundice (hyperbilirubinaemia).
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 8/54 3/46 100% 2.27[0.64,8.07]
   
Total (95% CI) 54 46 100% 2.27[0.64,8.07]
Total events: 8 (Self-monitoring), 3 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.27(P=0.2)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.10.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 10 Major anomalies.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 1/56 3/46 100% 0.27[0.03,2.54]
   
Total (95% CI) 56 46 100% 0.27[0.03,2.54]
Total events: 1 (Self-monitoring), 3 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.25)  
Favours self-monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Analysis 2.11.   Comparison 2 Self-monitoring versus hospitalisation, Outcome 11 Antenatal hospital admission.
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 10/54 46/46 100% 0.19[0.11,0.33]
   
Total (95% CI) 54 46 100% 0.19[0.11,0.33]
Total events: 10 (Self-monitoring), 46 (Hospitalisation)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=5.92(P<0.0001)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
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Analysis 2.12.   Comparison 2 Self-monitoring versus
hospitalisation, Outcome 12 Feeding di;iculties (not pre-specified).
Study or subgroup Self-monitoring Hospitalisation Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Hanson 1984 11/54 11/46 100% 0.85[0.41,1.78]
   
Total (95% CI) 54 46 100% 0.85[0.41,1.78]
Total events: 11 (Self-monitoring), 11 (Hospitalisation)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.43(P=0.67)  
Favours self monitoring 1000.01 100.1 1 Favours hospitalisation
 
 
Comparison 3.   Pre-prandial versus post-prandial glucose monitoring
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pre-eclampsia 1 58 Risk Ratio (M-H, Fixed, 95%
CI)
6.43 [0.82, 50.11]
2 Caesarean section 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
1.45 [0.92, 2.28]
3 Large-for-gestational age 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
1.16 [0.73, 1.85]
4 Perinatal mortality 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
2.91 [0.12, 68.66]
5 Weight gain during pregnancy 1 61 Mean Difference (IV, Fixed,
95% CI)
-0.90 [-3.86, 2.06]
6 Insulin dose 1 61 Mean Difference (IV, Fixed,
95% CI)
-17.40 [-43.41, 8.61]
7 Glycaemic control - Insulin dose 1 61 Mean Difference (IV, Fixed,
95% CI)
-0.20 [-0.45, 0.05]
8 Glycaemic control - HbA1c 1 61 Mean Difference (IV, Fixed,
95% CI)
0.30 [-0.08, 0.68]
9 Stillbirth 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
2.91 [0.12, 68.66]
10 Gestational age at birth 1 61 Mean Difference (IV, Fixed,
95% CI)
0.20 [-0.84, 1.24]
11 Preterm birth < 37 weeks 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
1.33 [0.62, 2.84]
Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
66
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
12 Macrosomia 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
2.18 [0.75, 6.32]
13 Birthweight 1 61 Mean Difference (IV, Fixed,
95% CI)
0.24 [-0.10, 0.58]
14 Adiposity - Subscapula skinfold thickness 1 61 Mean Difference (IV, Fixed,
95% CI)
0.60 [-0.18, 1.38]
15 Adiposity - Triceps skinfold thickness 1 61 Mean Difference (IV, Fixed,
95% CI)
0.60 [0.04, 1.16]
16 Birth trauma (shoulder dystocia, bone
fracture, nerve palsy) (not pre-specified as a
composite)
1 61 Risk Ratio (M-H, Fixed, 95%
CI)
0.48 [0.05, 5.06]
17 Respiratory distress syndrome 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
0.97 [0.06, 14.78]
18 Neonatal hypoglycaemia 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
1.09 [0.48, 2.45]
19 Neonatal jaundice (hyperbilirubinaemia) 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
1.16 [0.40, 3.40]
20 Cord IGF-1 1 61 Mean Difference (IV, Fixed,
95% CI)
1.30 [-0.70, 3.30]
21 Neonatal glucose at age 1 hour (not pre-
specified)
1 61 Mean Difference (IV, Fixed,
95% CI)
-0.20 [-0.88, 0.48]
22 Transient tachypnea (not pre-specified) 1 61 Risk Ratio (M-H, Fixed, 95%
CI)
2.58 [0.76, 8.81]
23 Neonatal intensive care admissions 1 59 Risk Ratio (M-H, Fixed, 95%
CI)
1.04 [0.62, 1.74]
 
 
Analysis 3.1.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 1 Pre-eclampsia.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 6/28 1/30 100% 6.43[0.82,50.11]
   
Total (95% CI) 28 30 100% 6.43[0.82,50.11]
Total events: 6 (Pre-prandial), 1 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.78(P=0.08)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
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Analysis 3.2.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 2 Caesarean section.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 21/31 14/30 100% 1.45[0.92,2.28]
   
Total (95% CI) 31 30 100% 1.45[0.92,2.28]
Total events: 21 (Pre-prandial), 14 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.61(P=0.11)  
Favours pre-prandial 1000.01 100.1 1 Favours post-prandial
 
 
Analysis 3.3.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 3 Large-for-gestational age.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 18/31 15/30 100% 1.16[0.73,1.85]
   
Total (95% CI) 31 30 100% 1.16[0.73,1.85]
Total events: 18 (Pre-prandial), 15 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.63(P=0.53)  
Favours pre-prandial 1000.01 100.1 1 Favours post-prandial
 
 
Analysis 3.4.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 4 Perinatal mortality.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 1/31 0/30 100% 2.91[0.12,68.66]
   
Total (95% CI) 31 30 100% 2.91[0.12,68.66]
Total events: 1 (Pre-prandial), 0 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
 
 
Analysis 3.5.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 5 Weight gain during pregnancy.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 15 (5.2) 30 15.9 (6.5) 100% -0.9[-3.86,2.06]
   
Total *** 31   30   100% -0.9[-3.86,2.06]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
Favors Post-prandial 52.5-5 -2.5 0 Favors Pre-prandial
Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
68
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
 
 
Analysis 3.6.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 6 Insulin dose.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 103 (51.3) 30 120.4 (52.3) 100% -17.4[-43.41,8.61]
   
Total *** 31   30   100% -17.4[-43.41,8.61]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
Favors Post-prandial 5025-50 -25 0 Favors Pre-prandial
 
 
Analysis 3.7.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 7 Glycaemic control - Insulin dose.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 1.2 (0.5) 30 1.4 (0.5) 100% -0.2[-0.45,0.05]
   
Total *** 31   30   100% -0.2[-0.45,0.05]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.56(P=0.12)  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
 
 
Analysis 3.8.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 8 Glycaemic control - HbA1c.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 6.3 (0.7) 30 6 (0.8) 100% 0.3[-0.08,0.68]
   
Total *** 31   30   100% 0.3[-0.08,0.68]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.56(P=0.12)  
Favours Pre-prandial 42-4 -2 0 Favours Post-prandial
 
 
Analysis 3.9.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 9 Stillbirth.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 1/31 0/30 100% 2.91[0.12,68.66]
   
Total (95% CI) 31 30 100% 2.91[0.12,68.66]
Total events: 1 (Pre-prandial), 0 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
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Analysis 3.10.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 10 Gestational age at birth.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 36.9 (1.5) 30 36.7 (2.5) 100% 0.2[-0.84,1.24]
   
Total *** 31   30   100% 0.2[-0.84,1.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.38(P=0.71)  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
 
 
Analysis 3.11.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 11 Preterm birth < 37 weeks.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 11/31 8/30 100% 1.33[0.62,2.84]
   
Total (95% CI) 31 30 100% 1.33[0.62,2.84]
Total events: 11 (Pre-prandial), 8 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.74(P=0.46)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
 
 
Analysis 3.12.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 12 Macrosomia.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 9/31 4/30 100% 2.18[0.75,6.32]
   
Total (95% CI) 31 30 100% 2.18[0.75,6.32]
Total events: 9 (Pre-prandial), 4 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.43(P=0.15)  
Favours pre-prandial 1000.01 100.1 1 Favours post-prandial
 
 
Analysis 3.13.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 13 Birthweight.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 3.5 (0.7) 30 3.3 (0.7) 100% 0.24[-0.1,0.58]
   
Total *** 31   30   100% 0.24[-0.1,0.58]
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Favours Pre-prandial 21-2 -1 0 Favours Post-prandial
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Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=1.4(P=0.16)  
Favours Pre-prandial 21-2 -1 0 Favours Post-prandial
 
 
Analysis 3.14.   Comparison 3 Pre-prandial versus post-prandial glucose
monitoring, Outcome 14 Adiposity - Subscapula skinfold thickness.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 6.3 (1.7) 30 5.7 (1.4) 100% 0.6[-0.18,1.38]
   
Total *** 31   30   100% 0.6[-0.18,1.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
 
 
Analysis 3.15.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 15 Adiposity - Triceps skinfold thickness.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 5.1 (1.3) 30 4.5 (0.9) 100% 0.6[0.04,1.16]
   
Total *** 31   30   100% 0.6[0.04,1.16]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.1(P=0.04)  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
 
 
Analysis 3.16.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 16
Birth trauma (shoulder dystocia, bone fracture, nerve palsy) (not pre-specified as a composite).
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 1/31 2/30 100% 0.48[0.05,5.06]
   
Total (95% CI) 31 30 100% 0.48[0.05,5.06]
Total events: 1 (Pre-prandial), 2 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.61(P=0.54)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
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Analysis 3.17.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 17 Respiratory distress syndrome.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 1/31 1/30 100% 0.97[0.06,14.78]
   
Total (95% CI) 31 30 100% 0.97[0.06,14.78]
Total events: 1 (Pre-prandial), 1 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.02(P=0.98)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
 
 
Analysis 3.18.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 18 Neonatal hypoglycaemia.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 9/31 8/30 100% 1.09[0.48,2.45]
   
Total (95% CI) 31 30 100% 1.09[0.48,2.45]
Total events: 9 (Pre-prandial), 8 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.21(P=0.84)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
 
 
Analysis 3.19.   Comparison 3 Pre-prandial versus post-prandial glucose
monitoring, Outcome 19 Neonatal jaundice (hyperbilirubinaemia).
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 6/31 5/30 100% 1.16[0.4,3.4]
   
Total (95% CI) 31 30 100% 1.16[0.4,3.4]
Total events: 6 (Pre-prandial), 5 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.27(P=0.79)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
 
 
Analysis 3.20.   Comparison 3 Pre-prandial versus post-prandial glucose monitoring, Outcome 20 Cord IGF-1.
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 8.6 (4.5) 30 7.3 (3.4) 100% 1.3[-0.7,3.3]
   
Total *** 31   30   100% 1.3[-0.7,3.3]
Heterogeneity: Not applicable  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
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Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=1.28(P=0.2)  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
 
 
Analysis 3.21.   Comparison 3 Pre-prandial versus post-prandial glucose
monitoring, Outcome 21 Neonatal glucose at age 1 hour (not pre-specified).
Study or subgroup Pre-prandial Post-prandial Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Manderson 2003 31 2.2 (1.5) 30 2.4 (1.2) 100% -0.2[-0.88,0.48]
   
Total *** 31   30   100% -0.2[-0.88,0.48]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.58(P=0.56)  
Favors Post-prandial 21-2 -1 0 Favors Pre-prandial
 
 
Analysis 3.22.   Comparison 3 Pre-prandial versus post-prandial glucose
monitoring, Outcome 22 Transient tachypnea (not pre-specified).
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 8/31 3/30 100% 2.58[0.76,8.81]
   
Total (95% CI) 31 30 100% 2.58[0.76,8.81]
Total events: 8 (Pre-prandial), 3 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favours Pre-prandial 1000.01 100.1 1 Favours Post-prandial
 
 
Analysis 3.23.   Comparison 3 Pre-prandial versus post-prandial
glucose monitoring, Outcome 23 Neonatal intensive care admissions.
Study or subgroup Pre-prandial Post-prandial Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Manderson 2003 15/30 14/29 100% 1.04[0.62,1.74]
   
Total (95% CI) 30 29 100% 1.04[0.62,1.74]
Total events: 15 (Pre-prandial), 14 (Post-prandial)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.13(P=0.89)  
Favours pre-prandial 1000.01 100.1 1 Favours post-prandial
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Comparison 4.   Automated telemedicine monitoring versus conventional
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Caesarean section 1 32 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.62, 1.48]
2 Neonatal morbidity compos-
ite
1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.53, 2.62]
3 Weight gain during pregnan-
cy [kg]
1 32 Mean Difference (IV, Fixed, 95% CI) -0.70 [-4.95, 3.55]
4 Use of additional insulin
therapy
1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.89, 1.12]
5 Insulin requirement at end of
study
1 20 Mean Difference (IV, Fixed, 95% CI) 18.4 [12.88, 23.92]
6 Glycaemic control - Maternal
fasting blood glucose: before
breakfast
1 20 Mean Difference (IV, Fixed, 95% CI) -1.0 [-1.22, -0.78]
7 Glycaemic control - Maternal
fasting blood glucose: before
lunch
1 20 Mean Difference (IV, Fixed, 95% CI) -1.10 [-1.32, -0.88]
8 Glycaemic control - Maternal
HbA1c
3 82 Mean Difference (IV, Random, 95% CI) -0.17 [-0.82, 0.48]
9 Glycaemic control - Maternal
post-prandial blood glucose
2 50 Mean Difference (IV, Random, 95% CI) -0.80 [-1.67, 0.08]
10 Gestational age at birth 3 84 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.14, 0.39]
11 Macrosomia 1 32 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.31, 4.43]
12 Birthweight 1 32 Mean Difference (IV, Fixed, 95% CI) -0.16 [-0.64, 0.32]
 
 
Analysis 4.1.   Comparison 4 Automated telemedicine
monitoring versus conventional, Outcome 1 Caesarean section.
Study or subgroup Telemedicine Conventional Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Dalfrà 2009 12/17 11/15 100% 0.96[0.62,1.48]
   
Total (95% CI) 17 15 100% 0.96[0.62,1.48]
Total events: 12 (Telemedicine), 11 (Conventional)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.17(P=0.86)  
Favours telemedicine 1000.01 100.1 1 Favours conventional
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Analysis 4.2.   Comparison 4 Automated telemedicine monitoring
versus conventional, Outcome 2 Neonatal morbidity composite.
Study or subgroup Telemedicine Conventional Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Dalfrà 2009 8/17 6/15 100% 1.18[0.53,2.62]
   
Total (95% CI) 17 15 100% 1.18[0.53,2.62]
Total events: 8 (Telemedicine), 6 (Conventional)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Favours telemedicine 1000.01 100.1 1 Favours conventional
 
 
Analysis 4.3.   Comparison 4 Automated telemedicine monitoring
versus conventional, Outcome 3 Weight gain during pregnancy [kg].
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dalfrà 2009 17 11 (4) 15 11.7 (7.5) 100% -0.7[-4.95,3.55]
   
Total *** 17   15   100% -0.7[-4.95,3.55]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.32(P=0.75)  
Favours telemedicine 2010-20 -10 0 Favours conventional
 
 
Analysis 4.4.   Comparison 4 Automated telemedicine monitoring
versus conventional, Outcome 4 Use of additional insulin therapy.
Study or subgroup Telemedicine Conventional Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Dalfrà 2009 17/17 15/15 100% 1[0.89,1.12]
   
Total (95% CI) 17 15 100% 1[0.89,1.12]
Total events: 17 (Telemedicine), 15 (Conventional)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours telemedicine 20.5 1.50.7 1 Favours conventional
 
 
Analysis 4.5.   Comparison 4 Automated telemedicine monitoring
versus conventional, Outcome 5 Insulin requirement at end of study.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Di Biase 1997 10 54 (7) 10 35.6 (5.5) 100% 18.4[12.88,23.92]
   
Total *** 10   10   100% 18.4[12.88,23.92]
Heterogeneity: Not applicable  
Favours telemedicine 2010-20 -10 0 Favours conventional
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Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=6.54(P<0.0001)  
Favours telemedicine 2010-20 -10 0 Favours conventional
 
 
Analysis 4.6.   Comparison 4 Automated telemedicine monitoring versus conventional,
Outcome 6 Glycaemic control - Maternal fasting blood glucose: before breakfast.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Di Biase 1997 10 4.8 (0.3) 10 5.8 (0.2) 100% -1[-1.22,-0.78]
   
Total *** 10   10   100% -1[-1.22,-0.78]
Heterogeneity: Not applicable  
Test for overall effect: Z=8.77(P<0.0001)  
Favours telemedicine 21-2 -1 0 Favours conventional
 
 
Analysis 4.7.   Comparison 4 Automated telemedicine monitoring versus conventional,
Outcome 7 Glycaemic control - Maternal fasting blood glucose: before lunch.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Di Biase 1997 10 4.7 (0.3) 10 5.8 (0.2) 100% -1.1[-1.32,-0.88]
   
Total *** 10   10   100% -1.1[-1.32,-0.88]
Heterogeneity: Not applicable  
Test for overall effect: Z=9.65(P<0.0001)  
Favours telemedicine 21-2 -1 0 Favours conventional
 
 
Analysis 4.8.   Comparison 4 Automated telemedicine monitoring
versus conventional, Outcome 8 Glycaemic control - Maternal HbA1c.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Dalfrà 2009 17 6.7 (0.7) 15 6.5 (0.8) 32.66% 0.2[-0.32,0.72]
Di Biase 1997 10 5 (0.4) 10 5.7 (0.3) 37.86% -0.7[-1.01,-0.39]
Wojcicki 2001 15 6.8 (0.9) 15 6.7 (0.9) 29.48% 0.1[-0.54,0.74]
   
Total *** 42   40   100% -0.17[-0.82,0.48]
Heterogeneity: Tau2=0.27; Chi2=10.93, df=2(P=0); I2=81.71%  
Test for overall effect: Z=0.51(P=0.61)  
Favours Telemedicine 21-2 -1 0 Favours Conventional
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Analysis 4.9.   Comparison 4 Automated telemedicine monitoring versus
conventional, Outcome 9 Glycaemic control - Maternal post-prandial blood glucose.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Di Biase 1997 10 5.7 (0.3) 10 6.9 (0.3) 55.02% -1.2[-1.46,-0.94]
Wojcicki 2001 15 7.3 (0.7) 15 7.6 (1) 44.98% -0.3[-0.92,0.32]
   
Total *** 25   25   100% -0.8[-1.67,0.08]
Heterogeneity: Tau2=0.35; Chi2=6.9, df=1(P=0.01); I2=85.51%  
Test for overall effect: Z=1.78(P=0.08)  
Favours Telemedicine 52.5-5 -2.5 0 Favours Conventional
 
 
Analysis 4.10.   Comparison 4 Automated telemedicine monitoring
versus conventional, Outcome 10 Gestational age at birth.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dalfrà 2009 17 36.1 (1.9) 15 35.1 (1.7) 4.53% 1[-0.25,2.25]
Di Biase 1997 10 37.8 (0.2) 10 37.7 (0.4) 91.64% 0.1[-0.18,0.38]
Wojcicki 2001 17 37 (2.2) 15 37.3 (1.7) 3.84% -0.3[-1.65,1.05]
   
Total *** 44   40   100% 0.13[-0.14,0.39]
Heterogeneity: Tau2=0; Chi2=2.3, df=2(P=0.32); I2=13.04%  
Test for overall effect: Z=0.93(P=0.35)  
Favours Conventional 21-2 -1 0 Favours Telemedicine
 
 
Analysis 4.11.   Comparison 4 Automated telemedicine monitoring versus conventional, Outcome 11 Macrosomia.
Study or subgroup Telemedicine Conventional Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Dalfrà 2009 4/17 3/15 100% 1.18[0.31,4.43]
   
Total (95% CI) 17 15 100% 1.18[0.31,4.43]
Total events: 4 (Telemedicine), 3 (Conventional)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.24(P=0.81)  
Favours telemedicine 1000.01 100.1 1 Favours conventional
 
 
Analysis 4.12.   Comparison 4 Automated telemedicine monitoring versus conventional, Outcome 12 Birthweight.
Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Dalfrà 2009 17 3.3 (0.7) 15 3.5 (0.7) 100% -0.16[-0.64,0.32]
   
Total *** 17   15   100% -0.16[-0.64,0.32]
Heterogeneity: Not applicable  
Favours telemedicine 10.5-1 -0.5 0 Favours conventional
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Study or subgroup Telemedicine Conventional Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Test for overall effect: Z=0.65(P=0.51)  
Favours telemedicine 10.5-1 -0.5 0 Favours conventional
 
 
Comparison 5.   Continuous glucose monitoring versus intermittent glucose monitoring
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Pre-eclampsia 2 225 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.52, 3.59]
2 Caesarean section 2 225 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.65, 1.54]
3 Large-for-gestational age 2 221 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.41, 1.92]
4 Perinatal mortality 1 71 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.05, 12.61]
5 Glycaemic control - Maternal HbA1c 1 71 Mean Difference (IV, Fixed, 95%
CI)
-0.60 [-0.91, -0.29]
6 Miscarriage 2 228 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.28, 5.24]
7 Neonatal mortality 1 74 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.05, 12.39]
8 Gestational age at birth 1 68 Mean Difference (IV, Fixed, 95%
CI)
0.10 [-0.57, 0.77]
9 Preterm birth < 37 weeks 2 228 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.63, 1.94]
10 Small-for-gestational age 1 67 Risk Ratio (M-H, Fixed, 95% CI) 7.34 [0.41, 131.18]
11 Birthweight 1 67 Mean Difference (IV, Fixed, 95%
CI)
-0.29 [-0.59, 0.01]
12 Neonatal hypoglycaemia 2 228 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.51, 1.16]
13 Major anomalies 1 74 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.05, 12.39]
14 Neonatal intensive care unit admis-
sions
1 74 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.48, 3.05]
 
 
Analysis 5.1.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 1 Pre-eclampsia.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 2/38 0/33 7.99% 4.36[0.22,87.67]
Secher 2013 7/79 6/75 92.01% 1.11[0.39,3.15]
Favours continuous 1000.01 100.1 1 Favours intermittent
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Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 117 108 100% 1.37[0.52,3.59]
Total events: 9 (Continuous monitoring), 6 (Intermittent monitoring)  
Heterogeneity: Tau2=0; Chi2=0.73, df=1(P=0.39); I2=0%  
Test for overall effect: Z=0.64(P=0.53)  
Favours continuous 1000.01 100.1 1 Favours intermittent
 
 
Analysis 5.2.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 2 Caesarean section.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Murphy 2008 27/38 19/33 51.81% 1.23[0.86,1.76]
Secher 2013 28/79 33/75 48.19% 0.81[0.54,1.19]
   
Total (95% CI) 117 108 100% 1[0.65,1.54]
Total events: 55 (Continuous monitoring), 52 (Intermittent monitoring)  
Heterogeneity: Tau2=0.06; Chi2=2.64, df=1(P=0.1); I2=62.08%  
Test for overall effect: Z=0.02(P=0.98)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Analysis 5.3.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 3 Large-for-gestational age.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Murphy 2008 13/37 18/30 47.71% 0.59[0.35,0.99]
Secher 2013 34/79 25/75 52.29% 1.29[0.86,1.94]
   
Total (95% CI) 116 105 100% 0.89[0.41,1.92]
Total events: 47 (Continuous monitoring), 43 (Intermittent monitoring)  
Heterogeneity: Tau2=0.26; Chi2=5.43, df=1(P=0.02); I2=81.59%  
Test for overall effect: Z=0.31(P=0.76)  
Favours continuous 1000.01 100.1 1 Favours intermittent
 
 
Analysis 5.4.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 4 Perinatal mortality.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 1/39 1/32 100% 0.82[0.05,12.61]
Favours Continuous 1000.01 100.1 1 Favours Intermittent
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Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 39 32 100% 0.82[0.05,12.61]
Total events: 1 (Continuous monitoring), 1 (Intermittent monitoring)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.14(P=0.89)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Analysis 5.5.   Comparison 5 Continuous glucose monitoring versus intermittent
glucose monitoring, Outcome 5 Glycaemic control - Maternal HbA1c.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Murphy 2008 38 5.8 (0.6) 33 6.4 (0.7) 100% -0.6[-0.91,-0.29]
   
Total *** 38   33   100% -0.6[-0.91,-0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=3.85(P=0)  
Favours Continuous 52.5-5 -2.5 0 Favours Intermittent
 
 
Analysis 5.6.   Comparison 5 Continuous glucose monitoring
versus intermittent glucose monitoring, Outcome 6 Miscarriage.
Study or subgroup Continuous Intermittent Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 1/41 1/33 35.07% 0.8[0.05,12.39]
Secher 2013 3/79 2/75 64.93% 1.42[0.24,8.29]
   
Total (95% CI) 120 108 100% 1.21[0.28,5.24]
Total events: 4 (Continuous), 3 (Intermittent)  
Heterogeneity: Tau2=0; Chi2=0.12, df=1(P=0.73); I2=0%  
Test for overall effect: Z=0.25(P=0.8)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Analysis 5.7.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 7 Neonatal mortality.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 1/41 1/33 100% 0.8[0.05,12.39]
   
Total (95% CI) 41 33 100% 0.8[0.05,12.39]
Total events: 1 (Continuous monitoring), 1 (Intermittent monitoring)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
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Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.88)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Analysis 5.8.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 8 Gestational age at birth.
Study or subgroup Continuous Intermittent Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Murphy 2008 36 37.6 (1.3) 32 37.5 (1.5) 100% 0.1[-0.57,0.77]
   
Total *** 36   32   100% 0.1[-0.57,0.77]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.29(P=0.77)  
Favours Intermittent 10.5-1 -0.5 0 Favours Continuous
 
 
Analysis 5.9.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 9 Preterm birth < 37 weeks.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 6/41 6/33 35.07% 0.8[0.29,2.26]
Secher 2013 16/79 12/75 64.93% 1.27[0.64,2.49]
   
Total (95% CI) 120 108 100% 1.1[0.63,1.94]
Total events: 22 (Continuous monitoring), 18 (Intermittent monitoring)  
Heterogeneity: Tau2=0; Chi2=0.51, df=1(P=0.47); I2=0%  
Test for overall effect: Z=0.34(P=0.73)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Analysis 5.10.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 10 Small-for-gestational age.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 4/37 0/30 100% 7.34[0.41,131.18]
   
Total (95% CI) 37 30 100% 7.34[0.41,131.18]
Total events: 4 (Continuous monitoring), 0 (Intermittent monitoring)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.36(P=0.18)  
Favours continuous 1000.01 100.1 1 Favours intermittent
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Analysis 5.11.   Comparison 5 Continuous glucose monitoring
versus intermittent glucose monitoring, Outcome 11 Birthweight.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Murphy 2008 37 3.3 (0.8) 30 3.6 (0.5) 100% -0.29[-0.59,0.01]
   
Total *** 37   30   100% -0.29[-0.59,0.01]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.87(P=0.06)  
Favours Continuous 42-4 -2 0 Favours Intermittent
 
 
Analysis 5.12.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 12 Neonatal hypoglycaemia.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 3/41 5/33 15.7% 0.48[0.12,1.87]
Secher 2013 25/79 29/75 84.3% 0.82[0.53,1.26]
   
Total (95% CI) 120 108 100% 0.77[0.51,1.16]
Total events: 28 (Continuous monitoring), 34 (Intermittent monitoring)  
Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%  
Test for overall effect: Z=1.27(P=0.2)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Analysis 5.13.   Comparison 5 Continuous glucose monitoring versus
intermittent glucose monitoring, Outcome 13 Major anomalies.
Study or subgroup Continuous
monitoring
Intermittent
monitoring
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 1/41 1/33 100% 0.8[0.05,12.39]
   
Total (95% CI) 41 33 100% 0.8[0.05,12.39]
Total events: 1 (Continuous monitoring), 1 (Intermittent monitoring)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.16(P=0.88)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Techniques of monitoring blood glucose during pregnancy for women with pre-existing diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
82
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Analysis 5.14.   Comparison 5 Continuous glucose monitoring versus intermittent
glucose monitoring, Outcome 14 Neonatal intensive care unit admissions.
Study or subgroup Continuous Intermittent Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Murphy 2008 9/41 6/33 100% 1.21[0.48,3.05]
   
Total (95% CI) 41 33 100% 1.21[0.48,3.05]
Total events: 9 (Continuous), 6 (Intermittent)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.4(P=0.69)  
Favours Continuous 1000.01 100.1 1 Favours Intermittent
 
 
Comparison 6.   Constant CGM versus intermittent CGM
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Caesarean section 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.33, 1.79]
2 Weight gain during pregnancy 1 25 Mean Difference (IV, Fixed, 95% CI) 0.5 [-1.82, 2.82]
3 Insulin dosage, 3rd trimester
(IU/kg/day)
1 25 Mean Difference (IV, Fixed, 95% CI) -0.03 [-1.30, 1.24]
4 Glycaemic control - Maternal
blood glucose (1st trimester)
1 25 Mean Difference (IV, Fixed, 95% CI) -0.5 [-2.70, 1.70]
5 Glycaemic control - Maternal
blood glucose (3rd trimester)
1 25 Mean Difference (IV, Fixed, 95% CI) -0.14 [-2.00, 1.72]
6 Glycaemic control - Maternal
HbA1c (1st trimester)
1 25 Mean Difference (IV, Fixed, 95% CI) -0.30 [-1.13, 0.53]
7 Glycaemic control - Maternal
HbA1c (3rd trimester)
1 25 Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.69, 0.51]
8 Maternal hypoglycemia 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.54 [0.06, 5.24]
9 Diabetic ketoacidosis (not pre-
specified)
1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.02, 8.05]
10 Preterm birth < 37 weeks 1 25 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.08, 15.46]
11 Macrosomia 1 25 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.08, 15.46]
12 Neonatal hypoglycaemia 1 25 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 6.1.   Comparison 6 Constant CGM versus intermittent CGM, Outcome 1 Caesarean section.
Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Petrovski 2011 5/12 7/13 100% 0.77[0.33,1.79]
   
Total (95% CI) 12 13 100% 0.77[0.33,1.79]
Total events: 5 (Constant CGM), 7 (Intermittent CGM)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
Favours Constant CGM 1000.01 100.1 1 Favours Intermittent CGM
 
 
Analysis 6.2.   Comparison 6 Constant CGM versus intermittent CGM, Outcome 2 Weight gain during pregnancy.
Study or subgroup Constant CGM Intermittent CGM Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Petrovski 2011 12 13.4 (3.1) 13 12.9 (2.8) 100% 0.5[-1.82,2.82]
   
Total *** 12   13   100% 0.5[-1.82,2.82]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.42(P=0.67)  
Favours constant CGM 105-10 -5 0 Favours intermittent CGM
 
 
Analysis 6.3.   Comparison 6 Constant CGM versus intermittent
CGM, Outcome 3 Insulin dosage, 3rd trimester (IU/kg/day).
Study or subgroup Constant CGM Intermittent CGM Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Petrovski 2011 12 0.9 (1.3) 13 0.9 (1.9) 100% -0.03[-1.3,1.24]
   
Total *** 12   13   100% -0.03[-1.3,1.24]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
Favours constant CGM 105-10 -5 0 Favours intermittent CGM
 
 
Analysis 6.4.   Comparison 6 Constant CGM versus intermittent CGM,
Outcome 4 Glycaemic control - Maternal blood glucose (1st trimester).
Study or subgroup Constant CGM Intermittent CGM Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Petrovski 2011 12 6.9 (2.1) 13 7.4 (3.4) 100% -0.5[-2.7,1.7]
   
Total *** 12   13   100% -0.5[-2.7,1.7]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.45(P=0.66)  
Favours Constant CGM 2010-20 -10 0 Favours Intermittent CGM
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Analysis 6.5.   Comparison 6 Constant CGM versus intermittent CGM,
Outcome 5 Glycaemic control - Maternal blood glucose (3rd trimester).
Study or subgroup Constant CGM Intermittent CGM Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Petrovski 2011 12 6.2 (2.8) 13 6.3 (1.8) 100% -0.14[-2,1.72]
   
Total *** 12   13   100% -0.14[-2,1.72]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.15(P=0.88)  
Favours Constant CGM 2010-20 -10 0 Favours Intermittent CGM
 
 
Analysis 6.6.   Comparison 6 Constant CGM versus intermittent CGM,
Outcome 6 Glycaemic control - Maternal HbA1c (1st trimester).
Study or subgroup Constant CGM Intermittent CGM Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Petrovski 2011 12 6.5 (1.3) 13 6.8 (0.7) 100% -0.3[-1.13,0.53]
   
Total *** 12   13   100% -0.3[-1.13,0.53]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.71(P=0.48)  
Favours Constant CGM 52.5-5 -2.5 0 Favours Intermittent CGM
 
 
Analysis 6.7.   Comparison 6 Constant CGM versus intermittent CGM,
Outcome 7 Glycaemic control - Maternal HbA1c (3rd trimester).
Study or subgroup Constant CGM Intermittent CGM Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Petrovski 2011 12 6.1 (0.9) 13 6.2 (0.6) 100% -0.09[-0.69,0.51]
   
Total *** 12   13   100% -0.09[-0.69,0.51]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.29(P=0.77)  
Favours Constant CGM 52.5-5 -2.5 0 Favours Intermittent CGM
 
 
Analysis 6.8.   Comparison 6 Constant CGM versus intermittent CGM, Outcome 8 Maternal hypoglycemia.
Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Petrovski 2011 1/12 2/13 100% 0.54[0.06,5.24]
   
Total (95% CI) 12 13 100% 0.54[0.06,5.24]
Total events: 1 (Constant CGM), 2 (Intermittent CGM)  
Favours Constant CGM 1000.01 100.1 1 Favours Intermittent CGM
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Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.6)  
Favours Constant CGM 1000.01 100.1 1 Favours Intermittent CGM
 
 
Analysis 6.9.   Comparison 6 Constant CGM versus intermittent
CGM, Outcome 9 Diabetic ketoacidosis (not pre-specified).
Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Petrovski 2011 0/12 1/13 100% 0.36[0.02,8.05]
   
Total (95% CI) 12 13 100% 0.36[0.02,8.05]
Total events: 0 (Constant CGM), 1 (Intermittent CGM)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.65(P=0.52)  
Favours constant CGM 1000.01 100.1 1 Favours intermittent CGM
 
 
Analysis 6.10.   Comparison 6 Constant CGM versus intermittent CGM, Outcome 10 Preterm birth < 37 weeks.
Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Petrovski 2011 1/12 1/13 100% 1.08[0.08,15.46]
   
Total (95% CI) 12 13 100% 1.08[0.08,15.46]
Total events: 1 (Constant CGM), 1 (Intermittent CGM)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
Favours Constant CGM 1000.01 100.1 1 Favours Intermittent CGM
 
 
Analysis 6.11.   Comparison 6 Constant CGM versus intermittent CGM, Outcome 11 Macrosomia.
Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Petrovski 2011 1/12 1/13 100% 1.08[0.08,15.46]
   
Total (95% CI) 12 13 100% 1.08[0.08,15.46]
Total events: 1 (Constant CGM), 1 (Intermittent CGM)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.06(P=0.95)  
Favours constant CGM 1000.01 100.1 1 Favours intermittent CGM
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Analysis 6.12.   Comparison 6 Constant CGM versus intermittent CGM, Outcome 12 Neonatal hypoglycaemia.
Study or subgroup Constant CGM Intermit-
tent CGM
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Petrovski 2011 0/12 0/13   Not estimable
   
Total (95% CI) 12 13 Not estimable
Total events: 0 (Constant CGM), 0 (Intermittent CGM)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours Constant CGM 1000.01 100.1 1 Favours Intermittent CGM
 
W H A T ' S   N E W
 
Date Event Description
30 November 2016 New citation required but conclusions
have not changed
One new trial added and the conclusions remain unchanged.
30 November 2016 New search has been performed Search updated, seven trial reports identified. One new trial
added for this update from ongoing studies (Dalfrà 2009). The re-
view now includes 10 trials. 'Risk of bias' assessments for blind-
ing have been updated to include assessments of both perfor-
mance and detection bias. 'Summary of findings' tables have
been incorporated.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
1. For this update, in order to improve consistency across reviews, we have used the Cochrane Pregnancy and Childbirth core outcome set
for reviews of diabetes in pregnancy, developed by the Cochrane Pregnancy and Childbirth Australasian satellite.
The outcomes specified in the last version of the review have been expanded to incorporate the core outcome set, but were as follows.
Primary outcomes
Maternal
1. Glycaemic control (HbA1c, fructosamine, fasting blood glucose, post-prandial blood glucose)
Infant
1. Birthweight
2. Macrosomia greater than 4.5 kg
Secondary outcomes
Maternal
1. Frequency of hypoglycaemia
2. Antenatal hospital stay (percentage requiring admission, length of stay)
3. Induction of labour
4. Caesarean section rates
5. Miscarriage
Infant
1. Gestational age (at birth) or preterm birth less than 37/less than 34 weeks
2. Frequency of neonatal hypoglycaemia
3. Shoulder dystocia
4. Major and minor anomalies
5. Neonatal intensive care admissions
6. Death of baby including stillbirth/neonatal death
to the following.
2. The following outcomes were not pre-specified.
1. Birth trauma (shoulder dystocia, bone fracture, nerve palsy) (not pre-specified as a composite)
2. Neonatal glucose at age one hour
3. Transient tachypnoea
4. Diabetic ketoacidosis
5. Feeding diHiculties
3. We have added 'Summary of findings' tables and an assessment of the quality of the evidence using the GRADE approach.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Pregnancy Outcome;  Blood Glucose Self-Monitoring  [*methods];  Cesarean Section  [statistics & numerical data];  Diabetes Mellitus,
Type 1  [*blood];  Diabetes Mellitus, Type 2  [*blood];  Fasting  [blood];  Glycated Hemoglobin A  [analysis];  Hospitalization;  Perinatal
Mortality;  Postprandial Period;  Pregnancy Complications, Cardiovascular  [epidemiology];  Pregnancy in Diabetics  [*blood];  Premature
Birth  [epidemiology];  Randomized Controlled Trials as Topic;  Telemedicine
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MeSH check words
Female; Humans; Infant, Newborn; Pregnancy
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